SEARCH

Search Details

OMURA Tomohiro
University Hospital / Department of Pharmacy
Associate Professor

Researcher basic information

■ Research Keyword
  • 薬学
  • 医療薬学
  • 薬理学
  • 神経化学
  • 神経変性疾患
  • パーキンソン病
  • 小胞体ストレス
  • microRNA
■ Research Areas
  • Life sciences / Clinical pharmacy
  • Life sciences / Pharmaceuticals - health and biochemistry
  • Life sciences / Neuroscience - general
■ Committee History
  • Apr. 2024 - Present, 兵庫県病院薬剤師会, 常任理事
  • Mar. 2021 - Present, 日本医療薬学会, 代議員
  • Jul. 2020 - Present, 日本医療薬学会, JPHCS編集委員会 委員
  • Apr. 2023 - Mar. 2024, 兵庫県病院薬剤師会, 理事
  • Apr. 2022 - Mar. 2024, 日本薬学会, ファルマシアトピックス小委員
  • Jul. 2019 - Jun. 2022, 日本病院薬剤師会, 学術第５小委員会（現・第２小委員会） 委員
  • Sep. 2016 - Mar. 2019, 日本医療薬学会, 薬物療法専門薬剤師・認定薬剤師認定試験問題作成小委員会 委員
  • Apr. 2015 - Mar. 2019, 日本医療薬学会, 薬物療法専門薬剤師・認定薬剤師認定試験実行小委員会 委員
  • Apr. 2014 - May 2016, 日本病院薬剤師会, がん専門薬剤師部門研修委員会 委員

Research activity information

■ Paper
  • Naoki Tamura, Kotaro Itohara, Yo Ueda, Yumi Kitahiro, Kazuhiro Yamamoto, Tomohiro Omura, Toshiyasu Sakane, Jun Saegusa, Ikuko Yano
    Background Valganciclovir (VGCV) is the first-line drug for preemptive therapy of cytomegalovirus (CMV) infections. However, even when administered at the dose specified in the package insert, there is significant interindividual variability in the plasma concentrations of ganciclovir (GCV). In addition, correlations have been reported between the area under the concentration–time curve and therapeutic efficacy or adverse events. Therefore, therapeutic drug monitoring (TDM) can be used to improve the efficacy and safety of preemptive VGCV therapy. Objective This study aims to evaluate whether the dosage adjustment of VGCV based on TDM in patients undergoing preemptive therapy for CMV infections is associated with the successful completion rate of treatment without severe hematological adverse effects. Methods This phase II, single-center, single-arm trial aims to enroll 40 patients admitted at the Department of Rheumatology and Clinical Immunology, Kobe University Hospital, who will receive oral VGCV as preemptive therapy for CMV infections. Participants will begin treatment with VGCV at the dose recommended in the package insert, with subsequent dose adjustments based on weekly TDM results. The primary end point will be the proportion of patients who achieve CMV antigenemia negativity within 3 weeks without severe hematological adverse events. The secondary end points will include weekly changes in CMV antigen levels, total VGCV dose, and duration of preemptive therapy. For safety evaluation, the occurrence, type, and severity of VGCV-related adverse events will be analyzed. Additionally, this study will explore the correlations between the efficacy and safety of preemptive therapy and the pharmacokinetic parameters of GCV, CMV-polymerase chain reaction values, and nudix hydrolase 15 (NUDT15) genetic polymorphisms. The correlation between GCV plasma concentrations obtained from regular venous blood and blood concentrations will be examined using dried blood spots. Results This study began with patient recruitment in September 2024, with 5 participants enrolled as of June 16, 2025. The target enrollment is 40 participants, and the anticipated study completion is set for July 2027. Conclusions This is the first study to investigate the impact of TDM intervention in patients receiving VGCV as preemptive therapy. The findings are postulated to provide valuable evidence regarding the utility of TDM in patients receiving VGCV as preemptive therapy. Trial Registration Japan Registry of Clinical Trials jRCTs051240080; https://jrct.mhlw.go.jp/latest-detail/jRCTs051240080 International Registered Report Identifier (IRRID) DERR1-10.2196/72549
    JMIR Publications Inc., Jun. 2025, JMIR Research Protocols, 14, e72549 - e72549, English
    [Refereed]
    Scientific journal

  • Takeshi Kimura, Shinichi Hikasa, Masashi Ishihara, Mariko Tsukiji, Yusuke Kunimoto, Kazuko Nobori, Kenta Onishi, Yuuki Yamamoto, Kyohei Haruta, Yohei Kashiwabara, Kenji Fujii, Kazuhiro Yamamoto, Tomohiro Omura, Kei Ebisawa, Goh Ohji, Kentaro Iwata, Ikuko Yano
    Elsevier BV, Jun. 2025, Journal of Infection and Chemotherapy, 31(6) (6), 102711 - 102711, English
    [Refereed]
    Scientific journal

  • Yumi Kitahiro, Mari Hashimoto, Yukako Sonda, Miki Yagi, Kotaro Itohara, Takumi Kido, Kazumichi Fujioka, Hitomi Imafuku, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Torasemide, a loop diuretic, is rarely used for pregnant women because of the risk of reduced placental blood flow resulting from decreased circulating plasma volume. We experienced a case of a newborn with metabolic alkalosis and mild polyuria. The mother was suspected of self-medicating as we detected torasemide in the neonatal serum by LC-MS/MS method. CASE PRESENTATION: A Japanese pregnant woman in her 20s with mental illness, symptoms of panic and eating disorders, and a history of overdosing on over-the-counter medications, was referred to our hospital for birth control. She presented with vomiting following bulimia nervosa and hypokalemia. Her baby was delivered vaginally at 36 weeks and 4 days of gestation. The baby's blood gas analysis on day 0 revealed metabolic alkalosis (pH > 7.42, HCO3- > 28 mmHg). Up to 16 h after birth, mild polyuria and a urine output of 3.3 mL/kg/h were observed without the administration of diuretics. We suspected diuretic intake by the mother before delivery, because she had a history of taking torasemide before being referred to the hospital. As expected, torasemide was detected in the baby's serum. The serum concentration on the first day after delivery (4.80 ng/mL) gradually decreased to 0.45 ng/mL on day 5, whereas torasemide was not detected in the maternal serum. Neonatal metabolic alkalosis improved by day 3 following birth. CONCLUSIONS: This case suggests close counseling and monitoring of pregnant women before childbirth regarding their past and present use of drugs, particularly in those with mental illness.
    Apr. 2025, Journal of pharmaceutical health care and sciences, 11(1) (1), 31 - 31, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 津田瑞季, 丹田雅明, 大村友博, 伊藤雄大, 飯田真之, 丸上奈穂, 山口由加里, 大本暢子, 山本和宏, 矢野 育子
    Japanese Society of Pharmaceutical Health Care and Sciences, Apr. 2025, 医療薬学, 51(4) (4), 203 - 212, Japanese
    [Refereed]
    Scientific journal

  • Prolonged Prothrombin Time due to Drug–Drug Interaction of Warfarin After the Change from Bosentan to Macitentan: A Case of Pharmacist Intervention in the Outpatient Clinic
    Kurimura T., Omura T., Yamamoto K., Tanaka H., Kumura T., Itohara K., Kitahiro Y., Habu Y., Sakane T., Yano I.
    Apr. 2025, Kobe Journal of Medical Sciences, 70(4) (4), E125 - E129, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Itohara, Kazuhiro Yamamoto, Shunsuke Fujinaka, Mari Hashimoto, Naoki Tamura, Yumi Kitahiro, Tomohiro Omura, Kazumichi Fujioka, Ikuko Yano
    BACKGROUND: Valganciclovir (VGCV) is administered at a dose of 16 mg/kg 2 times daily for 6 months to treat symptomatic congenital cytomegalovirus (CMV) infections. During the treatment period, approximately 20% of the patients developed grade 3 or higher neutropenia. Currently, information on the pharmacokinetics and pharmacodynamics of ganciclovir, an active metabolite of VGCV, in infants is limited. In the current study, the relationship between ganciclovir concentration and neutropenia was investigated, and a population pharmacokinetic (PPK) model of ganciclovir in infants with symptomatic congenital CMV infection was developed. METHODS: Japanese infants who were prescribed oral VGCV for symptomatic congenital CMV infections between July 2017 and January 2021 were included. The relationship between the observed trough ganciclovir concentrations and neutrophil counts was examined. PPK analysis was performed to evaluate the covariates affecting the pharmacokinetics of ganciclovir. RESULTS: Twenty-seven ganciclovir serum samples from 8 patients were analyzed. A moderate negative correlation was observed between the observed trough ganciclovir concentration and neutrophil count. PPK model analysis showed that postmenstrual age (PMA) affected the total body clearance of ganciclovir after correcting for the empirical allometric scaling of body weight. Based on PMA and body weight, a nomogram to achieve the target area under the concentration-time curve from 0 to 24 hours of 40-60 mcg·h·mL-1 of ganciclovir was calculated. CONCLUSIONS: The relationship between neutrophil count and ganciclovir trough concentration in infants was clarified. The PPK model showed that the dose of VGCV should be reduced in patients with a low PMA to achieve target exposure.
    Sep. 2024, Therapeutic drug monitoring, English, International magazine
    [Refereed]
    Scientific journal

  • Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, Atsushi Uda, Yuki Matsumoto, Naoki Tamura, Masashi Iida, Akiko Tanifuji, Kumiko Matsumoto, Naomi Mizuta, Kei Ebisawa, Goh Ohji, Tomohiro Omura, Kentaro Iwata, Ikuko Yano
    PURPOSE: While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to the United States. This study aimed to describe the distribution of DDIs with NMV-r and their management in patients with COVID-19 under the control of a management system for the appropriate use of NMV-r. METHODS: A retrospective observational study was conducted at a Japanese university hospital. The management system included a flowchart for selecting antivirals and a list for reviewing DDI management, based on the National Institutes of Health guidelines and the guidance of the Japanese Society of Pharmaceutical Health Care and Sciences. Patients with mild to moderate COVID-19 and prescribed NMV-r or molnupiravir (MOV) were included. The primary outcome was DDI management practices, including the selected COVID-19 medications. The secondary outcome included the distribution of DDI classification and the 30-day all-cause mortality. RESULTS: This study included 241 patients (median age of 60 years, 112 [46.5%] females), of whom 126 and 115 received NMV-r and MOV, respectively. Of the 241 patients, 145 (60.2%) received concomitant medications that have DDIs with NMV-r. All 30 patients with severe renal impairment or insufficient details on concomitant medications received MOV. Forty-nine patients with concomitant medications required alternative COVID-19 therapy consideration due to DDIs, of whom 42 (85.7%) patients received MOV. Eighty-one patients had concomitant medications requiring temporary adjustment, of whom 44 (54.3%) patients received NMV-r, and 42 of these patients temporarily adjusted these concomitant medications. Five patients with concomitant medications that can continued by monitoring the effects/adverse effects, of whom 4 (80.0%) patients received NMV-r. Seventy-six patients without concomitant medications requiring DDI management, of whom 71 (93.4%) patients received NMV-r. The 30-day all-cause mortality for eligible patients was 0.9% [95% confidence interval, 0.1-3.1]. CONCLUSIONS: Most patients received appropriate antivirals according to the classification of DDIs, and most patients with concomitant medications requiring temporary adjustment received the recommended DDI management. Our management system is effective in promoting the use of NMV-r in the appropriate patients and managing problematic DDIs.
    Sep. 2024, Journal of pharmaceutical health care and sciences, 10(1) (1), 54 - 54, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • オピオイド鎮痛薬を入院中に開始した外来頭頸部がん患者を対象とした病院薬剤師による電話サポート介入の効果
    志田 有里, 飯田 真之, 番匠 咲帆, 蓼原 瞬, 大本 暢子, 山本 和宏, 大村 友博, 丹生 健一, 矢野 育子
    (一社)日本緩和医療薬学会, Sep. 2024, 日本緩和医療薬学雑誌, 17(3) (3), 87 - 94, Japanese
    [Refereed]

  • Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
    Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is often required due to adverse events (AEs). This study aimed to evaluate the effect of early dose reduction of osimertinib on efficacy and safety. This was a retrospective study including patients with EGFR-mutated NSCLC who were started on osimertinib as the first-line therapy between August 2018 and December 2021. Patients whose doses were reduced to less than 80 mg/day within 6 months of osimertinib initiation or started at 40 mg/day were defined as the dose reduction group. The primary endpoint was progression-free survival (PFS). Factors affecting PFS were explored using the Cox proportional hazards model. A total of 85 patients were included in this study. No significant differences in patient characteristics were observed between the dose reduction (n = 25) and standard dose groups (n = 60). The median PFS in the dose reduction group was significantly prolonged compared with that in the standard dose group (26.0 months vs. 12.0 months, p = 0.03). Multivariable analysis of 84 patients, excluding a patient with unknown brain metastasis, revealed that EGFR exon 21 L858R mutation, malignant pleural effusion or pleural metastasis, liver metastasis, and dose reduction within 6 months were independent factors affecting PFS. Early dose reduction of osimertinib is an effective therapeutic strategy for prolonging PFS in patients with EGFR-mutated NSCLC.
    Jun. 2024, Investigational new drugs, 42(3) (3), 281 - 288, English, International magazine
    [Refereed]
    Scientific journal

  • 院外処方における臨床検査値を用いた2段階チェック機能の有用性：処方禁忌警告システムと処方せんへの検査値印字
    冨田猛, 山本和宏, 木村丈司, 宇田篤史, 土生康司, 大本暢子, 山下和彦, 大村友博, 矢野育子
    Jun. 2024, 医療薬学, 50(6) (6), 277 - 286, Japanese
    [Refereed]
    Scientific journal

  • Toru Konishi, Yumi Kitahiro, Naoko Fujiwara, Kazuhiro Yamamoto, Mari Hashimoto, Takahiro Ito, Kotaro Itohara, Kazumichi Fujioka, Hitomi Imafuku, Ikuo Otsuka, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Brexpiprazole is a second-generation antipsychotic approved in Japan in 2018; however, information on placental passage and breast milk transfer remains limited. In this report, the patient, a 30-year-old pregnant woman with schizophrenia, was medicated with brexpiprazole, risperidone, and quetiapine. METHODS: The study used high-performance liquid chromatography-tandem mass spectrometry to determine the concentrations of brexpiprazole, quetiapine, risperidone, and its active metabolite (paliperidone) in maternal and neonatal plasma, cord venous plasma, and breast milk. Maternal plasma samples were obtained approximately 2 and 8 hours after the last administration of antipsychotics on the day of delivery and at the estimated drugs' trough time on days 1, 3, and 5 after delivery. RESULTS: The maternal plasma concentrations of brexpiprazole, quetiapine, and paliperidone increased by approximately 3.5-fold on the fifth day compared with those on the day of delivery, whereas the risperidone concentration remained almost constant. Moreover, the neonatal plasma concentrations of the 4 drugs immediately after birth were indistinguishable from the umbilical cord concentrations and gradually decreased, except for risperidone. Relative infant doses of these compounds were below 1.1%. CONCLUSIONS: Pregnancy status notably alters the pharmacokinetic properties of antipsychotics. Therefore, close and careful monitoring of clinical symptoms should be considered during pregnancy and after delivery. Although brexpiprazole is transferred to neonates through the placenta, breastfeeding is still possible because the relative infant dose value of this drug was much less than 10%.
    Apr. 2024, Therapeutic drug monitoring, English, International magazine
    [Refereed]
    Scientific journal

  • 薬剤師によるバンコマイシン血中濃度測定オーダー登録と注射薬処方オーダー仮登録がもたらす実践的有用性の評価
    荻原孝史, 山本和宏, 村川亜光, 髙木妙子, 阪上倫行, 木村丈司, 藤田浩平, 宇田篤史, 大村友博, 矢野育子
    Apr. 2024, TDM研究, 41(4) (4), 117 - 124, Japanese
    [Refereed]
    Scientific journal

  • テルミサルタン錠の変色原因は添加剤のメグルミンによるドパミン誘導体の分解物である
    岡崎裕太朗, 大村友博, 上田昌史, 武田紀彦, 竹下治範, 飯田真之, 山下和彦, 木村丈司, 大本暢子, 山本和宏, 土生康司, 宮田興子, 矢野育子
    Apr. 2024, 日本病院薬剤師会雑誌, 60(4) (4), 395 - 401, Japanese
    [Refereed]
    Scientific journal

  • Tomoyuki Sakaue, Kazuhiro Yamamoto, Kotaro Itohara, Yumi Kitahiro, Takahito Endo, Naoki Yokoyama, Takeshi Ishimura, Tomohiro Omura, Ikuko Yano
    Elsevier BV, Mar. 2024, Drug Metabolism and Pharmacokinetics, 101009 - 101009
    [Refereed]
    Scientific journal

  • Yumi Kitahiro, Kazuhiro Yamamoto, Kimikazu Yakushijin, Takeshi Ioroi, Masaaki Tanda, Kotaro Itohara, Tomohiro Omura, Hironobu Minami, Ikuko Yano
    BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H1-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H1-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion. OBJECTIVE: This study aimed to assess the efficacy of first- and second-generation histamine H1-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma. METHODS: This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H1-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H1-receptor antagonist-induced drowsiness using the visual analogue scale, with each patient providing their individual response. RESULTS: This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026. CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.
    Feb. 2024, JMIR research protocols, 13, e54882, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 潜在的不適切処方の中止維持における退院時薬剤情報提供の効果
    古江由依, 山本和宏, 木村丈司, 高橋知子, 川瀬愛子, 清水倫子, 飯田真之, 松本久美子, 大本暢子, 山下和彦, 大村友博, 坂根稔康, 國正淳一, 矢野育子
    Feb. 2024, 医療薬学, 50(2) (2), 75 - 83, Japanese
    [Refereed]
    Scientific journal

  • Hiroki Nishiguchi, Tomohiro Omura, Ayaka Sato, Yumi Kitahiro, Kazuhiro Yamamoto, Junichi Kunimasa, Ikuko Yano
    Parkinson's Disease (PD) is caused by many factors and endoplasmic reticulum (ER) stress is considered as one of the responsible factors for it. ER stress induces the activation of the ubiquitin-proteasome system to degrade unfolded proteins and suppress cell death. The ubiquitin ligase 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation 1 (HRD1) and its stabilizing molecule, the suppressor/enhancer lin-12-like (SEL1L), can suppress the ER stress via the ubiquitin-proteasome system, and that HRD1 can also suppress cell death in familial and nonfamilial PD models. These findings indicate that HRD1 and SEL1L might be key proteins for the treatment of PD. Our study aimed to identify the compounds with the effects of upregulating the HRD1 expression and suppressing neuronal cell death in a 6-hydroxydopamine (6-OHDA)-induced cellular PD model. Our screening by the Drug Gene Budger, a drug repositioning tool, identified luteolin as a candidate compound for the desired modulation of the HRD1 expression. Subsequently, we confirmed that low concentrations of luteolin did not show cytotoxicity in SH-SY5Y cells, and used these low concentrations in the subsequent experiments. Next, we demonsrated that luteolin increased HRD1 and SEL1L mRNA levels and protein expressions. Furthermore, luteolin inhibited 6-OHDA-induced cell death and suppressed ER stress response caused by exposure to 6-OHDA. Finally, luteolin did not reppress 6-OHDA-induced cell death when expression of HRD1 or SEL1L was suppressed by RNA interference. These findings suggest that luteolin might be a novel therapeutic agent for PD due to its ability to suppress ER stress through the activation of HRD1 and SEL1L.
    Jan. 2024, Neurochemical research, 49(1) (1), 117 - 128, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomoko Kurimura, Kazuhiro Yamamoto, Hidekazu Tanaka, Takayoshi Toba, Takeshi Kimura, Yasushi Habu, Kotaro Itohara, Yumi Kitahiro, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Optimised antithrombotic therapy requires clinical experience and an understanding of the current guidelines. This retrospective study aimed to evaluate whether pharmacist interviews and interventions with patients taking oral antithrombotic drugs in the pharmaceutical outpatient cardiology clinic had favourable clinical outcomes including decreased bleeding. METHODS: The participants included patients visiting the outpatient clinic of cardiovascular internal medicine at the Kobe University Hospital from January-December 2017, and were taking oral antithrombotic medication. The observation period was from the first visit to the outpatient clinic to October 2021 or death. Patients who received pharmacist intervention more than twice were defined as the pharmacist intervention group. Two control patients per one pharmacist intervention group individual were selected from the non-intervention pool matched for age, gender and antithrombotic medication type. RESULTS: Of the 895 eligible patients, 132 were in the pharmacist intervention group and 264 were selected for the matched non-intervention group. Bleeding events according to the Bleeding Academic Research Consortium criteria over type 2 were significantly lower in the pharmacist intervention group compared with the non-intervention group (17.4% versus 28.4%, P = 0.019). There were no significant differences in mortality and heart failure hospitalisation frequency, stroke, or cardiovascular events between the groups. Multivariate analysis identified age (≥ 65 years) and pharmacist intervention as factors associated with bleeding (odds ratio = 2.29 and 0.51, respectively). CONCLUSION: Pharmacist intervention in the outpatient clinic of cardiovascular internal medicine was effective in reducing the risk of bleeding in patients undergoing antithrombotic therapy.
    Sep. 2023, Journal of pharmaceutical health care and sciences, 9(1) (1), 28 - 28, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 非がん性疼痛を有する患者のオピオイド使用状況モニタリングにおける薬剤師介入の効果
    飯田 真之, 大村 友博, 志田 有里, 番匠 咲帆, 大本 暢子, 山下 和彦, 槇本 博雄, 山本 和宏, 矢野 育子
    (一社)日本緩和医療薬学会, Sep. 2023, 日本緩和医療薬学雑誌, 16(3) (3), 65 - 71, Japanese
    [Refereed]

  • Takeshi Tomida, Kotaro Itohara, Kazuhiro Yamamoto, Takeshi Kimura, Kohei Fujita, Atsushi Uda, Yumi Kitahiro, Naoki Yokoyama, Yoji Hyodo, Tomohiro Omura, Ikuko Yano
    Sep. 2023, Drug Metabolism and Pharmacokinetics
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I
    Pharmaceutical Society of Japan, Jun. 2023, Biological and Pharmaceutical Bulletin, 46(6) (6), 788 - 795, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 退院支援関連業務への介入とアウトカム評価－日本病院薬剤師会令和3年度学術第2小委員会アンケートから－
    北田徳昭, 大村友博, 尾上雅英, 佐藤真由美, 柴田ゆうか, 堀内賢一, 宮崎俊明
    Apr. 2023, 日病薬誌, 59(4) (4), 401 - 407, Japanese
    [Refereed]

  • Masaaki Tanda, Kazuhiro Yamamoto, Tomoki Hori, Hiroki Nishiguchi, Miki Yagi, Michiko Shimizu, Toru Konishi, Tomonori Ozaki, Natsue Yoshioka, Motoko Tachihara, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
    BACKGROUND/AIM: Osimertinib is a key drug for treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Genetic differences may be associated to adverse events (AEs) induced by osimertinib. This retrospective observational multicenter study evaluated the association of genotypes, including STAT3 -1697C>G, CYP3A5 6986A>G, and ABCG2 421C>A, with the incidence of osimertinib-induced AEs in patients with EGFR mutation-positive NSCLC. PATIENTS AND METHODS: A total of 85 patients treated with osimertinib (Institution A: 33 patients, Institution B: 52 patients) were enrolled in the study. Single nucleotide polymorphisms were determined by real-time PCR, and the incidence of AEs was compared for each genotype. RESULTS: Paronychia incidence was 59% for the CC genotype, 19% for the CG genotype, and 19% for the GG genotype at STAT3 -1697C>G. A genotype-related trend was observed (Cochran-Armitage test, p=0.009). Multivariate analysis showed that the CC genotype at STAT3 -1697C>G and female sex were significant independent factors associated with paronychia [odds ratio (OR)=6.41, 95% confidence interval (CI)=1.94-21.20 and OR=3.40, 95%CI=1.03-11.22, respectively]. The incidence of diarrhea was 53% for the CC genotype, 30% for the AC genotype, and 29% for the AA genotype at ABCG2 421C>A, and a genotype-related trend was observed (p=0.048). However, the CC genotype at ABCG2 421C>A was not a significant independent factor associated with diarrhea in multivariate analysis. No significant associations were detected between other polymorphisms and the incidence of AEs. CONCLUSION: STAT3 -1697C>G may be a novel risk factor for osimertinib-induced paronychia in patients with NSCLC.
    Apr. 2023, Anticancer research, 43(4) (4), 1775 - 1783, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Daichi Enomoto, Kazuhiro Yamamoto, Yuki Matsumoto, Asami Morioka, Tomohiro Omura, Shohei Komatsu, Yoshihiko Yano, Takumi Fukumoto, Ikuko Yano
    BACKGROUND/AIM: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver function. The albumin-bilirubin (ALBI) grade is a novel indicator for predicting liver function in patients with hepatic disease. This study aimed to investigate the relationship between ALBI grade and HCC patients' lenvatinib treatment duration. PATIENTS AND METHODS: This is a retrospective cohort study of patients with HCC and Child-Pugh A treated with lenvatinib between April 2018 and December 2019. The baseline liver function was determined using the ALBI grade. The primary outcome was discontinuation owing to adverse events. The risk factors for discontinuation owing to adverse effects were analyzed using logistic regression. RESULTS: This investigation included 48 HCC patients. Patients with ALBI grade 2 had a significantly shorter time of discontinuation due to adverse events than those with grade 1 (p=0.036). However, the time of treatment failure did not differ between the groups. Multiple logistic regression analysis showed that ALBI grade 2 and non-use of antihypertensive drugs were independent factors for discontinuation due to adverse events [odds ratio (OR)=14.1, 95% confidence interval (CI)=1.46-135, p=0.022 and OR=5.48, 95% CI=1.13-23.9, p=0.024, respectively]. CONCLUSION: The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child-Pugh A.
    Mar. 2023, Anticancer research, 43(3) (3), 1317 - 1323, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Walaa Y B Mahdy, Kazuhiro Yamamoto, Takahiro Ito, Naoko Fujiwara, Kazumichi Fujioka, Tadasu Horai, Ikuo Otsuka, Hitomi Imafuku, Tomohiro Omura, Kazumoto Iijima, Ikuko Yano
    This study aimed to determine the effects of pregnancy and ontogeny on risperidone and paliperidone pharmacokinetics by assessing their serum concentrations in two subjects and constructing a customized physiologically-based pharmacokinetic (PBPK) model. Risperidone and paliperidone serum concentrations were determined in a pregnant woman and her newborn. PBPK models for risperidone and paliperidone in adults, pediatric, and pregnant populations were developed and verified using the Simcyp simulator. These models were then applied to our two subjects, generating their "virtual twins." Effects of pregnancy on both drugs were examined using models with fixed pharmacokinetic parameters. In the neonatal PBPK simulation, 10 different models for estimating the renal function of neonates were evaluated. Risperidone was not detected in the serum of both pregnant woman and her newborn. Maternal and neonatal serum paliperidone concentrations were between 2.05-3.80 and 0.82-1.03 ng/ml, respectively. Developed PBPK models accurately predicted paliperidone's pharmacokinetics, as shown by minimal bias and acceptable precision across populations. The individualized maternal model predicted all observed paliperidone concentrations within the 90% prediction interval. Fixed-parameter simulations showed that CYP2D6 activity largely affects risperidone and paliperidone pharmacokinetics during pregnancy. The Flanders metadata equation showed the lowest absolute bias (mean error: 22.3% ± 6.0%) and the greatest precision (root mean square error: 23.8%) in predicting paliperidone plasma concentration in the neonatal population. Our constructed PBPK model can predict risperidone and paliperidone pharmacokinetics in pregnant and neonatal populations, which could help with precision dosing using the PBPK model-informed approach in special populations.
    Jan. 2023, Clinical and translational science, 16(4) (4), 618 - 630, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 伊藤雄大, 丹田雅明, 水田直美, 丸上奈穂, 山口由加里, 植田梨沙, 梅山遥, 伊藤恵, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    (一社)日本病院薬剤師会, Jun. 2022, 日病薬誌, 58(6) (6), 627 - 632, Japanese
    [Refereed]
    Scientific journal

  • Kunimitsu Y, Morio K, Hirata S, Yamamoto K, Omura T, Hara T, Harada K, Fujisawa M, Yano I
    The gut microbiome influences tumor response to immune checkpoint inhibitors (ICIs). The proton pump inhibitors (PPI) significantly impair diversity of the gut microbiota and can affect the efficacy of ICIs. Therefore, the present study aimed to evaluate the influence of PPI on survival in patients with metastatic or unresectable urothelial carcinoma receiving pembrolizumab. We conducted a retrospective cohort study of patients with metastatic or unresectable urothelial carcinoma receiving pembrolizumab. The use of PPI was defined as any administration for ≥30 d within 60 d prior and/or 30 d after treatment initiation. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and Cox proportional hazards regression analysis was performed to investigate prognostic factors based on patient characteristics. Seventy-nine patients were included in the analysis, and 34 patients (43.0%) received PPI. There were no significant differences in OS and PFS between PPI users and nonusers (median OS: 8.2 months vs. 11.2 months, hazard ratio (HR): 1.36, 95% confidence interval (CI): 0.75-2.42, p = 0.296; median PFS: 3.5 months vs. 5.1 months, HR: 1.63, 95% CI: 0.95-2.80, p = 0.069). In the multivariable analysis, PPI use was not associated with OS (HR 0.80, 95% CI 0.40-1.56, p = 0.526) or PFS (HR 1.44, 95% CI 0.79-2.60, p = 0.233). In conclusion, the estimated effect size of PPI use on survival in Japanese patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab was not reproducible.
    May 2022, Biol Pharm Bull., 45(5) (5), 590 - 595, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Takeshi Ioroi, Kazuaki Shinomiya, Ayaka Yoshida, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Yasuaki Ikemi, Shunsaku Nakagawa, Atsushi Yonezawa, Osamu Ogawa, Kazuo Matsubara, Takuya Iwamoto, Kohei Nishikawa, Sayaka Hayashi, Daichi Tohara, Yoji Murakami, Takanobu Motoshima, Hirofumi Jono, Ikuko Yano
    We evaluated the association of signal transducer and activator of transcription 3 (STAT3) polymorphisms with the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in patients with renal cell carcinoma (RCC). We also used lung-derived cell lines to investigate the mechanisms of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (-1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD and therapeutic outcome. In the 57 patients included in the primary analysis, the ILD rate within 140 days was significantly higher in patients with the GG genotype compared with those with other genotypes (77.8% versus 23.1%, odds ratio = 11.67, 95% confidential interval = 3.06–44.46). Meanwhile, there were no significant differences in progression-free survival or time-to-treatment failure between the patients with the GG genotype and those with other genotypes. An in vitro study demonstrated that some lung-derived cell lines carrying the GG genotype exhibited an increase in the expression of mesenchymal markers, such as fibronectin, N-cadherin, and vimentin and decreases in E-cadherin, which is an epithelial marker associated with exposure to everolimus, although STAT3 expression and activity were not related to the genotype. In conclusion, the GG genotype of the STAT3 -1697C/G polymorphism increases the risk of mTOR inhibitor-induced ILD, supporting its use as a predictive marker for RCC.
    Cognizant, LLC, May 2022, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 29(1) (1), 11 - 23, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • ロフラゼプ酸エチル活性代謝物の褥婦母乳およびその児の血中濃度を測定した2症例
    森田真樹子, 米澤淳, 大村友博, 中川俊作, 志田あゆみ, 今井哲司, 河井昌彦, 松倉崇, 丹羽房子, 岩永甲午郎, 伊尾紳吾, 近藤英治, 松原和夫
    (一社)日本医療薬学会, Apr. 2022, 医療薬学, 48(4) (4), 149 - 153, Japanese
    [Refereed]
    Scientific journal

  • Matsuda Y, Nakagawa S, Yano I, Masuda S, Imai S, Yonezawa A, Yamamoto T, Sugimoto M, Tsuda M, Tsuzuki T, Omura T, Nakagawa T, Chen-Yoshikawa TF, Nagao M, Date H, Matsubara K
    Invasive Aspergillus infection is a major factor for poor prognosis in patients receiving lung transplantation (LT). An antifungal agent, itraconazole (ITCZ), that has antimicrobial activity against Aspergillus species, is used as a prophylactic agent against Aspergillus infection after LT. ITCZ and its metabolite, hydroxyitraconazole (OH-ITCZ), potently inhibit CYP3A and P-glycoprotein that metabolize or excrete calcineurin inhibitors (CNIs), which are the first-line immunosuppressants used after LT; thus, concomitant use of ITCZ and CNIs could induce an increase in the blood concentration of CNIs. However, no criteria for dose reduction of CNIs upon concomitant use with ITCZ in LT recipients have been defined. In this study, the effect of ITCZ and OH-ITCZ on the blood concentrations of two CNIs, tacrolimus and cyclosporine, after LT were retrospectively evaluated. A total of 39 patients who received LT were evaluated. Effects of ITCZ and OH-ITCZ on the concentration/dosage (C/D) ratio of tacrolimus and cyclosporine were analyzed using linear mixed-effects models. The plasma concentrations of OH-ITCZ were about 2.5-fold higher than those of ITCZ. Moreover, there was a significant correlation between the plasma concentrations of ITCZ and OH-ITCZ. Based on parameters obtained in the linear regression analysis, the C/D ratios of cyclosporine and tacrolimus increase by an average of 2.25- and 2.70-fold, respectively, when the total plasma concentration of ITCZ plus OH-ITCZ is 1000 ng/mL. In conclusion, the plasma levels of ITCZ and OH-ITCZ could be key factors in drawing up the criterion for dose reduction of CNIs.
    Apr. 2022, Biol Pharm Bull., 45(4) (4), 397-402 - 402, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Kimura T, Fujita M, Shimizu M, Sumiyoshi K, Bansho S, Yamamoto K, Omura T, Yano I
    BACKGROUND: Potentially inappropriate medications (PIMs) and polypharmacy in older adults lead to increase the risk of adverse drug events. This study aimed to evaluate the effectiveness of pharmacist intervention combining the criteria for detecting PIMs with the deprescribing algorithm on correcting PIMs, reducing the number of medications, and readmissions. METHODS: A prospective observational study was conducted at a Japanese University Hospital enrolling new inpatients aged ≥65 years prescribed ≥1 daily medication. Pharmacists detected PIMs based on the criteria combined the screening tool of older persons' potentially inappropriate prescriptions criteria version 2 with the screening tool for older persons' appropriate prescriptions for Japanese, examined changes using the deprescribing algorithm, and suggested changes to the physician. The proportion of patients whose number of medications was reduced at discharge and the rate of readmissions within 30 and 90 days were compared between patients without PIMs (without PIMs group), patients who were not suggested to change PIMs (no suggestions group), and patients who were suggested to change PIMs (suggested group). RESULTS: The study enrolled 544 patients (median age 75.0 years, 54.4% males, median number of medications 6.0/patient). The number of patients with PIMs was 240 (44.1%), and 304 patients had no PIMs (without PIMs group). Among the patients with PIMs, 125 (52.1%) patients received pharmacist suggestions to change ≥1 PIMs (suggested group), and 115 patients received no suggestions for change (no suggestions group). The total number of PIMs was 432, of which changes were suggested for 189 (43.8%). Of these 189 cases, 172 (91.0%) were changed. The proportion of patients whose number of medications was reduced was significantly higher in the suggested group than in the without PIMs group and the no suggestions group [56.8% (71/125) vs. 26.6% (81/304) and 19.1% (22/115), respectively; P < 0.001 in both comparisons]. There were no significant differences in the rates of readmissions within 30 and 90 days among the three groups. CONCLUSIONS: Pharmacist intervention combining the criteria for detecting PIMs with the deprescribing algorithm was effective for correcting PIMs and may be associated with a reduction in the number of medications.
    Apr. 2022, J Pharm Health Care Sci., 8(1) (1), 12 - 12, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Satoshi Nishiyama, Makoto Kunisada, Masashi Iida, Takahiro Ito, Takeshi Ioroi, Hiroo Makimoto, Tomohiro Omura, Kenichi Harada, Masato Fujisawa, Chikako Nishigori, Ikuko Yano
    Abstract Background Hand-foot skin reaction (HFSR) induced by multiple tyrosine kinase inhibitors (TKIs) is a serious side effect that can cause treatment interruption or decreased dosing. This study was conducted to evaluate the safety and efficacy of bis-glyceryl ascorbate (Amitose bis(di)-glyceryl ascorbate [DGA])-containing cream (DGA cream) for the prevention of sunitinib-induced HFSR. Methods A single-arm, open-label phase I/II study was conducted, targeting patients with metastatic renal cell carcinoma (mRCC) who were receiving sunitinib therapy with a schedule of 2 weeks on/1 week off. The participants applied DGA cream to both palmar and plantar surfaces in combination with a moisturizing agent as standard-of-care prophylaxis during two sunitinib treatment cycles (6 weeks). The primary endpoint in phase I was safety defined as dermatological abnormalities and it was determined in the first five participants. The primary endpoint in phase II was efficacy defined as development of grade 1 or higher HFSR defined by Common Terminology Criteria for Adverse Events within 6 weeks and it was determined on a full analysis set (FAS) defined as the population including all participants who used DGA cream once in the study duration. Efficacy in the per protocol set (PPS) defined as the population excluding seven patients whose study treatment was interrupted was evaluated as a secondary endpoint. Results Twenty-four patients were enrolled as a FAS. No dermatological abnormalities occurred in the first 5 patients enrolled in the phase I study. Three patients developed HFSR (grade 1: n = 2, grade 2: n = 1) in the observation period. The HFSR incidence rate was 12.5% (3/24; 95% confidence interval [CI]: 2.7%-32.4%) in the FAS, which was significantly lower than the incidence rate predefined as a threshold of 33.3% by a previous report from our hospital (P = .030). The incidence rate in the 17 patients of the PPS was 17.6% (3/17; 95%CI: 3.8%-43.4%). Conclusion DGA cream may be safe and effective in the prophylaxis of HFSR in mRCC patients who receive sunitinib therapy (Trial ID: jRCTs051180051).
    Oxford University Press (OUP), Mar. 2022, The Oncologist, 27(5) (5), e384-e392, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Itohara, Ikuko Yano, Shunsaku Nakagawa, Atsushi Yonezawa, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Atsuro Sawada, Takashi Kobayashi, Akira Tochio, Kaoru Sakai, Kojiro Taura, Osamu Ogawa, Kazuo Matsubara
    Elsevier BV, Feb. 2022, Drug Metabolism and Pharmacokinetics, 42, 100423 - 100423, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • がん化学療法誘発性悪心・嘔吐の予防を目的としたオランザピンの投与量と傾眠発現との関連
    穐原裕奈, 山本和宏, 水田直美, 丹田雅明, 伊藤雄大, 大村友博, 坂根稔康, 國正淳一, 矢野育子
    Jan. 2022, 日本病院薬剤師会雑誌, 58(1) (1), 67 - 72, Japanese
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Luna Nomura, Ran Watanabe, Hiroki Nishiguchi, Kazuhiro Yamamoto, Satoshi Imai, Shunsaku Nakagawa, Kotaro Itohara, Atsushi Yonezawa, Takayuki Nakagawa, Junichi Kunimasa, Ikuko Yano, Kazuo Matsubara
    Endoplasmic reticulum (ER) stress has been reported as a cause of Parkinson’s disease (PD). We have previously reported that the ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) and its stabilizing factor suppressor/enhancer lin-12-like (SEL1L) participate in the ER stress. In addition, we recently demonstrated that neuronal cell death is enhanced in the cellular PD model when SEL1L expression is suppressed compared with cell death when HRD1 expression is suppressed. This finding suggests that SEL1L is a critical key molecule in the strategy for PD therapy. Thus, investigation into whether microRNAs (miRNAs) regulate SEL1L expression in neurons should be interesting because relationships between miRNAs and the development of neurological diseases such as PD have been reported in recent years. In this study, using miRNA databases and previous reports, we searched for miRNAs that could regulate SEL1L expression and examined the effects of this regulation on cell death in PD models created by 6-hydroxydopamine (6-OHDA). Five miRNAs were identified as candidate miRNAs that could modulate SEL1L expression. Next, SH-SY5Y cells were exposed to 6-OHDA, following which miR-101 expression was found to be inversely correlated with SEL1L expression. Therefore, we selected miR-101 as a candidate miRNA for SEL1L modulation. We confirmed that miR-101 directly targets the SEL1L 3′ untranslated region, and an miR-101 mimic suppressed the 6-OHDA–induced increase in SEL1L expression and enhanced cell death. Furthermore, an miR-101 inhibitor suppressed this response. These results suggest that miR-101 regulates SEL1L expression and may serve as a new target for PD therapy.
    Frontiers Media SA, Dec. 2021, Frontiers in Molecular Neuroscience, 14, 748026 - 748026, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takahiro Ito, Kazuhiro Yamamoto, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Ikuko Yano
    WHAT IS KNOWN AND OBJECTIVE: Sunitinib is used as a first-line therapy for metastatic renal cell carcinoma. The primary aim of this study was to determine the optimal total sunitinib (sunitinib plus N-desethyl sunitinib) trough concentration for the alternative dosing schedule: 2-week-on and 1-week-off schedule (2/1 schedule). METHODS: Patients with metastatic renal cell carcinoma treated with the 2/1 schedule of sunitinib, whose total sunitinib concentrations were available, were recruited for this study. Out of 19 patients, 17 whose sunitinib dosage was not changed until the measurement of drug concentration were eligible for the analysis of the relationship between total sunitinib concentration and clinical outcome. Individual pharmacokinetic parameters in 19 patients were estimated via the Bayesian analysis. RESULTS: The onset of severe (grade ≥3) adverse effects among 17 patients during 3 weeks as a first course of sunitinib therapy was observed in 7 (41.2%) patients. The median total sunitinib concentration in patients with severe adverse effects was significantly higher compared with that in patients without severe adverse effects [median: 119 (113-131) vs. 87.8 (77.4-102) ng/mL, p = 0.01]. According to the receiver operating characteristic analysis of the onset of severe adverse effects, the cut-off value of the total sunitinib concentration was 108 ng/mL. Patients with a total sunitinib concentration lower than 108 ng/mL had a longer time to first dose reduction or withdrawal due to adverse effects compared with those with a total sunitinib concentration of 108 ng/mL or higher (p = 0.03). The probability without treatment failure was not significantly different between the two concentration groups. In addition, the estimated sunitinib apparent oral clearance (CL/F) was significantly lower in the severe adverse effects group. Our simulation demonstrated that 0.67-time dose is needed for patients with approximately 90.0 ng/mL of sunitinib concentration on day 7 to maintain the concentration at the same level as the patients with higher CL/F. WHAT IS NEW AND CONCLUSION: Maintaining the total sunitinib trough concentrations of less than 108 ng/mL is safe to avoid the onset of serious adverse effects without increasing the treatment failure in patients with metastatic renal cell carcinoma treated with the 2/1 schedule of sunitinib.
    Wiley, Oct. 2021, Journal of Clinical Pharmacy and Therapeutics, 47(1) (1), 81 - 88, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yuko Nakayama, Kohji Takara, Tetsuya Minegaki, Kazuhiro Yamamoto, Tomohiro Omura, Ikuko Yano
    BACKGROUND/AIM: Resistance to venetoclax, a selective inhibitor of BCL2 apoptosis regulator (BCL2), is regarded as a clinical problem. However, it is unclear whether resistance to venetoclax induces cross-resistance to other drugs. MATERIALS AND METHODS: Venetoclax-resistant HL60/VEN cells were newly established through continuous exposure of human acute promyelocytic leukemia HL60 cells to venetoclax, and drug sensitivity, apoptotic activity, and mRNA expression were compared between HL60 and HL60/VEN cells. RESULTS: HL60/VEN cells displayed approximately 3-fold resistance to venetoclax, maintained their ability to synthesize DNA and had low apoptotic activity. HL60/VEN cells also exhibited diverse sensitivity to cytotoxic drugs, especially resistance to ATP binding cassette subfamily B member 1 (ABCB1) substrates, and up-regulation of ABCB1 mRNA. However, the sensitivity of HL60/VEN cells to venetoclax was not restored by ABCB1 inhibitor. ABCB1-overexpressing cells did not show resistance to venetoclax. CONCLUSION: HL60/VEN cells exhibited up-regulation of ABCB1 in addition to an alteration in apoptotic activity, and cross-resistance to ABCB1 substrates was clarified. However, sensitivity to venetoclax was hardly affected by ABCB1.
    Anticancer Research USA Inc., Sep. 2021, Anticancer Research, 41(9) (9), 4239 - 4248, English, International magazine
    [Refereed]
    Scientific journal

  • Madoka Koyanagi, Satoshi Imai, Mayuna Matsumoto, Yoko Iguma, Nobuko Kawaguchi-Sakita, Takeshi Kotake, Yuki Iwamitsu, Mpumelelo Ntogwa, Ren Hiraiwa, Kazuki Nagayasu, Mamiko Saigo, Takashi Ogihara, Atsushi Yonezawa, Tomohiro Omura, Shunsaku Nakagawa, Takayuki Nakagawa, Kazuo Matsubara
    American Association for Cancer Research (AACR), Apr. 2021, Cancer Research, 81(8) (8), 2207 - 2219, English
    [Refereed]
    Scientific journal

  • 消化管上皮細胞モデルにおけるABCB1発現・機能に及ぼすエベロリムス長期曝露の影響
    中山 優子, 高良 恒史, 山本 和宏, 大村 友博, 矢野 育子
    (公社)日本薬学会, Mar. 2021, 日本薬学会年会要旨集, 141年会, 29P01 - 289, Japanese

  • Ayaka Yoshida, Kazuhiro Yamamoto, Takahiro Ishida, Tomohiro Omura, Tomoo Itoh, Chikako Nishigori, Toshiyasu Sakane, Ikuko Yano
    Hand-foot skin reaction (HFSR) is a common side effect caused by several tyrosine kinase inhibitors, including sunitinib. However, the nature of the cornifying factors related to the molecular biological mechanisms underlying HFSR remains poorly understood. We used human keratinocyte models to investigate the key cornifying factors for dermatological and biological abnormalities induced by sunitinib. On the basis of the results of microarray analysis using the three-dimensional (3D) human epidermal model, keratin (KRT)6A, serine protease inhibitor (SERPIN)B1, KRT5, and SERPIN Kazal-type 6 were selected as candidate genes related to HFSR. Sunitinib treatment significantly decreased the expression of SERPINB1 and KRT6A in the immunohistochemical staining of the 3D epidermal model. In PSVK1 cells, but not in normal human epidermal keratinocyte cells, both of which are human normal keratinocyte cell lines, sunitinib decreased the expression of KRT6A with a concomitant decrease in levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated p38 mitogen-activated protein kinase (MAPK). Inhibitors of the ERK and p38 MAPK signal pathways also significantly decreased KRT6A expression. Sunitinib-induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase-3β by enhancing ERK1/2 and p38 MAPK phosphorylation. Thus, sunitinib reduces the expression of KRT6A and SERPINB1 by inhibiting the ERK1/2 and p38 MAPK signalling pathways in the skin model. These changes in expression contribute to the pathology of HFSR.
    Wiley, Mar. 2021, Experimental Dermatology, 30(3) (3), 337 - 346, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Joe Yamamoto, Tomohiro Omura, Sachiko Kasamo, Shota Yamamoto, Masayoshi Kawata, Atsushi Yonezawa, Yosuke Taruno, Hisako Endo, Hitoshi Aizawa, Nobukatsu Sawamoto, Kazuo Matsubara, Ryosuke Takahashi, Yoshikazu Tasaki
    In the pharmacotherapy of patients with Parkinson's disease (PD), entacapone reduces the peripheral metabolism of L-dopa to 3-O-methyldopa (3-OMD), thereby prolonging the half-life (t1/2) of L-dopa and increasing the area under the concentration curve (AUC). The effect of entacapone on the pharmacokinetics of L-dopa differs between patients with high-activity (H/H) and low-activity (L/L) catechol-O-methyltransferase (COMT) Val158Met polymorphisms, but the effects are unclear in heterozygous (H/L) patients. 3-OMD has a detrimental effect and results in a poor response to L-dopa treatment in patients with PD; however, the influence of this polymorphism on the production of 3-OMD remains unknown. Therefore, the present study aimed to clarify the effect of the COMT Val158Met polymorphism on the concentrations of L-dopa and 3-OMD in the presence of entacapone. We performed an open-label, single-period, single-sequence crossover study at two sites in Japan. The study included 54 Japanese patients with PD, who underwent an acute L-dopa administration test with and without 100 mg entacapone on two different days. Entacapone increased L-dopa AUC0-infinity by 1.59 ± 0.26-fold in the H/H group, which was significantly higher than that in the H/L (1.41 ± 0.36-fold) and L/L (1.28 ± 0.21-fold) groups (p < 0.05). The concurrent administration of L-dopa with entacapone suppressed the increase in 3-OMD levels compared with L-dopa alone in all genotypes. Our results suggest that the COMT Val158Met polymorphism may be an informative biomarker for individualized dose adjustment of COMT inhibitors in the treatment of PD.
    Springer Science and Business Media LLC, Jan. 2021, Journal of Neural Transmission, 128(1) (1), 27 - 36, English, International magazine
    [Refereed]
    Scientific journal

  • 植田 梨沙, 丹田 雅明, 伊藤 雄大, 榎本 彩花, 飯田 真之, 水田 直美, 山本 和宏, 槇本 博雄, 大村 友博, 矢野 育子
    (一社)日本医療薬学会, Dec. 2020, 医療薬学, 46(12) (12), 681 - 691, Japanese
    [Refereed]

  • Congyun Jin, Atsushi Yonezawa, Hiroki Yoshimatsu, Satoshi Imai, Madoka Koyanagi, Kaori Yamanishi, Shunsaku Nakagawa, Kotaro Itohara, Tomohiro Omura, Takayuki Nakagawa, Junya Nagai, Kazuo Matsubara
    Abstract Riboflavin transporter 3 (RFVT3), encoded by the SLC52A3 gene, is important for riboflavin homeostasis in the small intestine, kidney, and placenta. Our previous study demonstrated that Slc52a3 knockout (Slc52a3−/−) mice exhibited neonatal lethality and metabolic disorder due to riboflavin deficiency. Here, we investigated the influence of Slc52a3 gene disruption on brain development using Slc52a3−/− embryos. Slc52a3−/− mice at postnatal day 0 showed hypoplasia of the brain and reduced thickness of cortical layers. At embryonic day 13.5, the formation of Tuj1+ neurons and Tbr2+ intermediate neural progenitors was significantly decreased; no significant difference was observed in the total number and proliferative rate of Pax6+ radial glia. Importantly, the hypoplastic phenotype was rescued upon riboflavin supplementation. Thus, it can be concluded that RFVT3 contributes to riboflavin homeostasis in embryos and that riboflavin itself is required during embryonic development of the cerebral cortex in mice.
    Springer Science and Business Media LLC, Dec. 2020, Scientific Reports, 10(1) (1), 18443 - 18443, English, International magazine
    [Refereed]
    Scientific journal

  • Miki Kondo, Shunsaku Nakagawa, Satoru Orii, Kotaro Itohara, Mitsuhiro Sugimoto, Tomohiro Omura, Yuki Sato, Satoshi Imai, Atsushi Yonezawa, Takayuki Nakagawa, Kazuo Matsubara
    Vancomycin is a glycopeptide antibiotic used for the treatment of Gram-positive infections. For adult patients, treatment with vancomycin requires effective therapeutic drug-monitoring (TDM) to achieve clinical outcomes and reduce the incidence of adverse effects. However, it remains still unclear whether the TDM with vancomycin is beneficial in yielding better clinical outcomes in pediatrics. The objective of our study was to evaluate whether the clinical response to treatment was associated with initial trough concentrations of vancomycin in pediatric patients. A retrospective observation study of 60 patients (age: 1 month-15 years) who had completed and qualified for analysis was conducted at Kyoto University Hospital. The response to treatment was assessed by the time to resolution of fever and time to 50% decline in C-reactive protein (CRP). In addition, we explored whether vancomycin trough level was associated with the baseline characteristics. Trend analysis showed that there were significant correlations between vancomycin trough level and age, body weight, estimated glomerular filtration rate, and serum albumin levels. The time to resolution of fever of the patients with higher initial trough level (≥ 5 µg/mL) was significantly lower than that of the patients with lower trough level (< 5 µg/mL). The higher vancomycin concentration tended to be associated with the shorter time to 50% decline in CRP. The findings suggest that initial trough concentration is important in achieving better outcomes with vancomycin treatment in pediatrics.
    Pharmaceutical Society of Japan, Oct. 2020, Biological and Pharmaceutical Bulletin, 43(10) (10), 1463 - 1468, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Takahiro Ito, Kazuhiro Yamamoto, Satoshi Ogawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Ikuko Yano
    Elsevier BV, Oct. 2020, Drug Metabolism and Pharmacokinetics, 35(5) (5), 405 - 409
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Mpumelelo Ntogwa, Satoshi Imai, Ren Hiraiwa, Madoka Koyanagi, Mayuna Matsumoto, Takashi Ogihara, Shunsaku Nakagawa, Tomohiro Omura, Atsushi Yonezawa, Takayuki Nakagawa, Kazuo Matsubara
    The neuroinflammatory responses to human immunodeficiency virus type 1 (HIV-1) coat proteins, such as glycoprotein 120 (gp120), are considered to be responsible for the HIV-associated distal sensory neuropathy. Accumulating evidences suggest that T-cell line tropic X4 gp120 increases macrophage infiltration into the peripheral nerves, and thereby induces neuroinflammation leading to pain. However, the mechanisms underlying X4 gp120-induced macrophage recruitment to the peripheral nervous systems remain unclear. Here, we demonstrated that perineural application of X4 gp120 from HIV-1 strains IIIB and MN elicited mechanical hypersensitivity and spontaneous pain-like behaviors in mice. Furthermore, flow cytometry and immunohistochemical studies revealed increased infiltration of bone marrow-derived macrophages into the parenchyma of sciatic nerves and dorsal root ganglia (DRG) 7 days after gp120 IIIB or MN application. Chemical deletion of circulating macrophages using clodronate liposomes markedly suppressed gp120 IIIB-induced pain-like behaviors. In in vitro cell infiltration analysis, RAW 264.7 cell (a murine macrophage cell line) was chemoattracted to conditioned medium from gp120 IIIB- or MN-treated cultured Schwann cells, but not to conditioned medium from these gp120-treated DRG neurons, suggesting possible involvement of Schwann cell-derived soluble factors in macrophage infiltration. We identified using a gene expression array that CXCL1, a chemoattractant of macrophages and neutrophils, was increased in gp120 IIIB-treated cultured Schwann cells. Similar to gp120 IIIB or MN, perineural application of recombinant CXCL1 elicited pain-like behaviors accompanied by macrophage infiltration to the peripheral nerves. Furthermore, the repeated injection of CXCR2 (receptor for CXCL1) antagonist or CXCL1 neutralizing antibody prevented both pain-like behaviors and macrophage infiltration in gp120 IIIB-treated mice. Thus, the present study newly defines that Schwann cell-derived CXCL1, secreted in response to X4 gp120 exposure, is responsible for macrophage infiltration into peripheral nerves, and is thereby associated with pain-like behaviors in mice. We propose herein that communication between Schwann cells and macrophages may play a prominent role in the induction of X4 HIV-1-associated pain.
    Aug. 2020, Brain, behavior, and immunity, 88, 325 - 339, English, International magazine
    [Refereed]
    Scientific journal

  • 吉田優子, 佐藤夕紀, 傳田将也, 池見泰明, 杉本充弘, 山際岳朗, 中川俊作, 今井哲司, 大村友博, 尾崎淳子, 深津祥央, 矢野育子, 北田徳昭, 米澤淳, 中川貴之, 松原和夫
    (一社)日本病院薬剤師会, Jun. 2020, 日本病院薬剤師会雑誌, 56(6) (6), 643 - 650, Japanese
    [Refereed]
    Scientific journal

  • Yunpeng Zhang, Atsushi Yonezawa, Shunsaku Nakagawa, Satoshi Imai, Masaya Denda, Tomohiro Omura, Takayuki Nakagawa, Kazuo Matsubara
    The clinical use of cisplatin is limited by its adverse events, particularly serious nephrotoxicity. It was clarified that cisplatin is transported by a kidney-specific organic cation transporter (OCT2). OCT2 also mediates the uptake of oxaliplatin into renal proximal tubular cells; however, this agent does not lead nephrotoxicity. In the present study, we carried out comparative experiments with cisplatin and oxaliplatin using porcine kidney LLC-PK1 cell monolayers. In the fluorescein-labeled isothiocyanate-dextran flux assay, the basolateral application of cisplatin, but not oxaliplatin, resulted in an increase in the paracellular permeability of cell monolayers. Even though the cellular accumulation of platinum at 50 μM oxaliplatin could reach the same level at 30 μM cisplatin, oxaliplatin did not induce hyper-permeability in cell monolayers. Cisplatin, but not oxaliplatin, significantly activated PKC. In addition, the combination of PKC inhibitors recovered the increase in paracellular permeability. In conclusion, pharmacodynamic mechanisms via PKC could explain the difference in nephrotoxicity between cisplatin and oxaliplatin.
    Feb. 2020, Drug metabolism and pharmacokinetics, 35(1) (1), 111 - 116, English, International magazine
    [Refereed]
    Scientific journal

  • Mikihiro Fujiya, Nobuhiro Ueno, Shin Kashima, Kazuyuki Tanaka, Aki Sakatani, Katsuyoshi Ando, Kentaro Moriichi, Hiroaki Konishi, Naoya Kamiyama, Yoshikazu Tasaki, Tomohiro Omura, Kazuo Matsubara, Masaki Taruishi, Toshikatsu Okumura
    The goal of ulcerative colitis (UC) treatment has recently been shown to be "mucosal healing," as no drug directly induces mucosal healing. Probiotics possess sufficient safety, but their efficacy in the treatment of UC remains controversial because of the influence of intestinal conditions. It is believed that the identification of bioactive molecules produced by probiotics and their application will help to solve this issue. We therefore identified a probiotic-derived long-chain polyphosphate as a molecule enhancing the intestinal barrier function. This study demonstrated that long-chain polyphosphate exhibited antiinflammatory effects in a human macrophage and interleukin-10 knockout transfusion mouse model. The first-in-human trial showed that 7 of the 10 enrolled patients acquired clinical remission, 4 of whom achieved endoscopic remission despite a history of treatment with anti-tumor necrosis factor (TNF)-α agents. No adverse reactions were observed. Long-chain polyphosphate might be useful for the treatment of refractory UC, even in patients with failure or intolerance to anti-TNF-α therapy.
    Feb. 2020, Clinical pharmacology and therapeutics, 107(2) (2), 452 - 461, English, International magazine
    [Refereed]
    Scientific journal

  • Hiromitsu Negoro, Takayuki Goto, Shusuke Akamatsu, Naoki Terada, Takashi Kobayashi, Yoshiyuki Matsui, Takashi Yamamoto, Tomohiro Omura, Atsushi Yonezawa, Kazuo Matsubara, Osamu Ogawa
    AIM: To assess the add-on effects of tadalafil in patients with a relatively small benign prostatic enlargement (BPE) treated with tamsulosin. METHODS: From September 2014 to July 2018, we prospectively studied patients (aged 50 years or more) attending our hospital who had received tamsulosin for small BPE (20-40 mL) for 4 weeks at least and still had residual lower urinary tract symptoms (LUTS) with total International Prostate Symptom Scores (IPSS) of at least 8 and IPSS-quality of life scores at least 3. We randomized eligible patients into two groups: one of which received tadalafil 5 mg once daily for 6 weeks, followed by placebo for 6 weeks, and the other of which received placebo followed by tadalafil in the same manner. The patients were reviewed at our outpatient clinic after 2, 6, 8, and 12 weeks. RESULTS: There were 13 patients in the tadalafil-placebo and 13 in the placebo-tadalafil group. Their median ages (range) were 70 (65-85) and 73 (50-80) years, prostatic volumes (median) 30.0 (22.0-39.7) and 32.0 (20.1-39.5) mL, and total IPSS (median) 17 (10-27) and 16 (10-24), respectively. The primary endpoints, namely mean changes of total IPSS from baseline, were 1.85 on placebo and -3.42 on tadalafil; this difference is statistically significant (difference: -1.57; 95% confidence interval: -3.00, -0.69; P = .032). We encountered no adverse effects. CONCLUSIONS: Add-on of tadalafil for symptomatic patients with small BPE treated with tamsulosin appears to be effective and safe.
    Jan. 2020, Neurourology and urodynamics, 39(1) (1), 237 - 242, English, International magazine
    [Refereed]

  • Takashi Ogihara, Takayuki Nakagawa, Maho Hayashi, Madoka Koyanagi, Atsushi Yonezawa, Tomohiro Omura, Shunsaku Nakagawa, Noriaki Kitada, Satoshi Imai, Kazuo Matsubara
    Oxaliplatin, a platinum-based chemotherapeutic drug, frequently induces peripheral neuropathy. Accumulating evidences suggest a possible relationship between peripheral vascular impairment and peripheral neuropathy. In this study, we investigated the effects of vasodilators on cumulative peripheral neuropathy induced by repeated injections of oxaliplatin (10 mg/kg) once a week for 8 weeks in mice. Single injections of vasodilators, including a phosphodiesterase type 5 inhibitor tadalafil acutely alleviated oxaliplatin-induced cold hypersensitivity, while tadalafil had no effect on the mechanical hypersensitivity. By contrast, long-term administration of tadalafil (0.1% in chow diets) during the oxaliplatin injection period reduced the oxaliplatin-induced decreases in skin temperature and blood flow without affecting platinum concentrations in blood, sciatic nerves, and dorsal root ganglion. The long-term administration significantly suppressed cold, mechanical, and electrical current hypersensitivities as well as thermal hypoesthesia. Furthermore, it prevented the decreases in sensory nerve conductance velocity and the number of endoneurial microvessels, and axon degeneration in the sciatic nerves. In vitro studies confirmed that tadalafil does not interfere with the cytotoxicity of oxaliplatin against human cancer cell lines. Altogether, these results suggest that improvement of peripheral vascular impairment by tadalafil could alleviate and prevent oxaliplatin-induced peripheral neuropathy.
    Dec. 2019, Journal of pharmacological sciences, 141(4) (4), 131 - 138, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Atushi Yonezawa, Yuki Otani, Toshiyuki Kitano, Mayuko Mori, Sho Masui, Yui Isomoto, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Makoto Hayakari, Akifumi Takaori-Kondo, Kazuo Matsubara
    PURPOSE: Therapeutic antibodies have heterogeneities in their structures, although its structural alteration in the body is unclear. Here, we analyzed the change of amino acid modifications and carbohydrate chains of rituximab after administration to patients. METHODS: Twenty B cell non-Hodgkin's lymphoma patients who were treated with rituximab for the first time or after more than one year's abstinence were recruited. Structural analysis of rituximab was carried out at 1 h after administration and at the trough by using liquid chromatography/time-of-flight-mass spectrometry. Plasma rituximab concentration and pharmacodynamic markers were also determined. RESULTS: Of recruited twenty, 3 patients exhibited rapid rituximab clearance. Nine types of carbohydrate chains were detected in rituximab isolated from the blood. The composition ratios in some glycoforms were significantly different between at 1 h after administration and at the trough, although consisted amino acids remained unchanged. The patients with high clearance showed extensive alterations of glycoform composition ratios. However, pharmacodynamics makers were not different. CONCLUSION: Inter-individual variations in plasma concentrations of rituximab were found in some B-NHL patients. We could analyze a change in glycoforms of rituximab in the patients, and this finding may affect the pharmacokinetics of rituximab.
    Apr. 2019, Pharmaceutical research, 36(6) (6), 82 - 82, English, International magazine
    [Refereed]
    Scientific journal

  • Yoshiki Katada, Shunsaku Nakagawa, Akiko Nishimura, Yu-Ki Sato, Hiromi Taue, Katsuyuki Matsumura, Kazuhiro Yamazaki, Kenji Minakata, Ikuko Yano, Tomohiro Omura, Satoshi Imai, Atsushi Yonezawa, Yuki Sato, Takayuki Nakagawa, Kenji Minatoya, Kazuo Matsubara
    PURPOSE: Warfarin shows large inter- and intra-individual variabilities in its pharmacokinetics and pharmacodynamics. Sufficient understanding of factors affecting the response to warfarin is necessary to achieve improved outcomes for warfarin therapy. In this study, we evaluated effects of fasting on the anticoagulant properties of warfarin. METHODS: We conducted a retrospective observational study involving a total of 58 patients, who received cardiovascular surgeries and subsequent warfarin therapy. The effect of dietary intake on the anticoagulant properties with warfarin was assessed by measurement of the international normalized ratio of prothrombin time (PT-INR): the anticoagulant activities of warfarin were expressed as the warfarin sensitivity index (WSI). Additionally, fluctuations in WSI during the study period were obtained as differences between the maximum and minimum WSI. RESULTS: The maximum PT-INR and WSI values were significantly higher for patients who were fasting for different reasons during the postoperative period than those in the group without reduced dietary intake. The differences between maximum and minimum WSI in the fasting group significantly increased compared with those in the groups with moderate or no reduced dietary intake. Meanwhile, effects of other markers of clinical conditions including the baseline Child-Pugh score and Charlson Comorbidity Index on WSI were not significant. CONCLUSIONS: Our results indicate that postoperative fasting was significantly associated with the anticoagulation activity of warfarin. In patients fasting for different reasons during the postoperative period, closer control of PT-INR values and warfarin adjustments may be required to avoid adverse effects such as bleeding in warfarin treatment.
    Apr. 2019, European journal of clinical pharmacology, 75(4) (4), 561 - 568, English, International magazine
    [Refereed]
    Scientific journal

  • Tsuda M, Otani Y, Yonezawa A, Masui S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Imai S, Nakagawa T, Hayakari M, Matsubara K
    Pharmaceutical Society of Japan, Nov. 2018, Biological & pharmaceutical bulletin, 41(11) (11), 1716 - 1721
    [Refereed]
    Scientific journal

  • Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Matsubara K
    Nov. 2018, Biochemical and biophysical research communications, 506(3) (3), 516 - 521
    [Refereed]

  • Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Tasaki Y, Matsubara K
    We have previously reported that oxicam-derived non-steroidal anti-inflammatory drugs (oxicam-NSAIDs), including meloxicam, piroxicam and tenoxicam, elicit protective effects against 1-methyl-4-phenyl pyridinium (MPP+)-induced cell death in a fashion independent of cyclooxygenase (COX) inhibition. We have also demonstrated that oxicam-NSAIDs suppress the decrease in phosphorylation of Akt caused by MPP+. The molecular mechanism through which oxicam-NSAIDs provide cytoprotection remains unclear. In this study, we speculated a possibility that endoplasmic reticulum (ER) stress and/or mitochondrial dysfunction, which are both causative factors of Parkinson's disease (PD), may be involved in the neuroprotective mechanism of oxicam-NSAIDs. We demonstrated here that oxicam-NSAIDs suppressed the activation of caspase-3 and cell death caused by MPP+ or ER stress-inducer, tunicamycin, in SH-SY5Y cells. Furthermore, oxicam-NSAIDs suppressed the increases in the ER stress marker CHOP (apoptosis mediator) caused by MPP+ or tunicamycin, beside suppressing eukaryotic initiation factor 2α (eIF2α) phosphorylation and the increase in ATF4 caused by MPP+. Taken together, these results suggest that oxicam-NSAIDs suppress the eIF2α-ATF4-CHOP pathway, one of the three signaling pathways in the ER stress response. Oxicam-NSAIDs suppressed the decrease in mitochondrial membrane potential depolarization caused by MPP+, indicating they also rescue cells from mitochondrial dysfunction. Akt phosphorylation levels were suppressed after the incubation with MPP+, whereas phosphorylation of eIF2α was enhanced. These results suggest that oxicam-NSAIDs prevented eIF2α phosphorylation and mitochondrial dysfunction by maintaining Akt phosphorylation (reduced by MPP+), thereby preventing cell death.
    Sep. 2018, Biochemical and biophysical research communications, 503(4) (4), 2963 - 2969, English, International magazine
    [Refereed]
    Scientific journal

  • Medical Economic Effects of Prescriptions with “Management of Unused Medicines” Pre-Printed as an Instruction from Prescribing Physician
    Fukatsu S, Ikemi Y, Yonezawa A, Yamamoto H, Ozaki J, Asano M, Sakurai K, Uesugi M, Yoshida Y, Denda M, Otani Y, Omura T, Imai S, Nakagawa S, Nakagawa T, Imai H, Matsubara K
    Mar. 2018, Journal of Japanese Society of Hospital Pharmacists, 54(3) (3), 307 - 312
    [Refereed]

  • Chisato Hoshina, Tomohiro Omura, Katsuhiro Okuda, Hiroki Tanaka, Masaru Asari, Shotaro Isozaki, Kie Horioka, Hiromi Yamada, Hiroki Doi, Hiroshi Shiono, Kazuo Matsubara, Keiko Shimizu
    Elsevier B.V., 2018, Biochemical and Biophysical Research Communications, 503(2) (2), 809 - 814, English
    [Refereed]
    Scientific journal

  • Shunsaku Nakagawa, Mayumi Nakaishi, Motomu Hashimoto, Hiromu Ito, Wataru Yamamoto, Ran Nakashima, Masao Tanaka, Takao Fujii, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Atsushi Yonezawa, Hirohisa Imai, Tsuneyo Mimori, Kazuo Matsubara
    For the optimum efficacy of disease-modifying anti-rheumatic drugs (DMARDs), patients need to be adherent to their medication regimen. To clarify the effects of medication adherence on disease activity in Japanese patients with rheumatoid arthritis (RA), we conducted a cohort study in patients with various stages of RA. Patients were enrolled from the Kyoto University RA Management Alliance cohort, and followed up prospectively for 12 months. In this study, a total of 475 patients were analyzed and divided into 9 groups according to their medication adherence and the RA disease duration. The primary outcomes were based on the rate of a disease flare. The secondary outcomes were the changes in disease activity score using 28 joints (DAS28-ESR), simplified disease activity index (SDAI) and physical disability by health assessment questionnaire-disability index (HAQ). The changes in DAS28-ESR, HAQ, and the risk of disease flare in the highly adherent patients were significantly lower than those of the less adherent patients among the groups with RA ≤ 4.6 years but not those among the other groups. Taken together, this study identified a significant association between medication adherence and the disease flare during early-stage RA or short disease duration. These results emphasize the need to pay more attention to medication adherence in preventing the disease progression of RA.
    2018, PloS one, 13(11) (11), e0206943, English, International magazine
    [Refereed]
    Scientific journal

  • Congyun Jin, Yoshiaki Yao, Atsushi Yonezawa, Satoshi Imai, Hiroki Yoshimatsu, Yuki Otani, Tomohiro Omura, Shunsaku Nakagawa, Takayuki Nakagawa, Kazuo Matsubara
    Nov. 2017, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(11) (11), 1990 - 1995, English
    [Refereed]
    Scientific journal

  • Satoshi Imai, Madoka Koyanagi, Ziauddin Azimi, Yui Nakazato, Mayuna Matsumoto, Takashi Ogihara, Atsushi Yonezawa, Tomohiro Omura, Shunsaku Nakagawa, Shuji Wakatsuki, Toshiyuki Araki, Shuji Kaneko, Takayuki Nakagawa, Kazuo Matsubara
    Jul. 2017, SCIENTIFIC REPORTS, 7(1) (1), 5947, English
    [Refereed]
    Scientific journal

  • Yuki Otani, Atushi Yonezawa, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Kazuo Matsubara
    Jan. 2017, PLOS ONE, 12(1) (1), e0169588, English
    [Refereed]
    Scientific journal

  • 旭川医科大学法医学講座における過去10年間のDNA鑑定および血縁者・関与者の数学的評価
    浅利 優, 大村 友博, 奥田 勝博, 田中 宏樹, 山田 ひろみ, 塩野 寛, 松原 和夫, 清水 惠子
    法医学談話会, Nov. 2016, 法医学の実際と研究, (59) (59), 175 - 178, Japanese
    [Refereed]

  • Kengo Matsumura, Yuki Otani, Tomohiro Omura, Atsushi Yonezawa, Masahiro Tsuda, Yasuaki Ikemi, Shunsaku Nakagawa, Satoshi Imai, Takayuki Nakagawa, Ikuko Yano, Tatsuhiro Yoshiki, Kazuo Matsubara

    Many biosimilars have been launched recently, however, a precise analytical method to evaluate their characteristics has not been developed. In this study, we established a new qualitative analysis technology for biomedicines using liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (LC/QTOF-MS), and assessed the original product and 4 biosimilars of filgrastim. Three peaks (Peak 1-3) appeared in total ion chromatogram by LC/QTOF-MS in the original brand-named drug. Filgrastim appeared as the main peak (Peak 1), and its molecular weight was calculated to be 18798.96 ± 0.02. When the original product was reduced by dithiothreitol, the molecular weight was 18802.19 ± 0.47, which was identical to the theoretical value based on amino acid sequence. These results indicate that it is possible to measure and distinguish molecular weights of untreated and reduced forms of filgrastim by LC/QTOF-MS. In addition, main peaks from all products including biosimilars showed exactly the same mass spectra and calculated molecular weights, suggesting that the main components (filgrastim) in these 4 products were considered to be qualitatively equal. On the other hand, the area ratios of 2 secondary peaks (Peaks 2 and 3) against the main peak (Peak 1) in 2 biosimilars were higher than those in the original product. The calculated molecular weights in Peaks 2 and 3 corresponded to that of polysorbate 80, which was one of the additives in the formulation. In conclusion, LC/QTOF-MS is a useful technique for qualitative component analysis of biomedicines.

    Japanese Society of Pharmaceutical Health Care and Sciences, Sep. 2016, Japanese Journal of Pharmaceutical Health Care and Sciences, 42(9) (9), 613 - 619, Japanese
    [Refereed]

  • Shimizu K, Omura T, Okuda K, Asari M, Shiono H, Matsubara K
    This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Following closely behind levels in Western countries, the number of drug-facilitated sexual assaults (DFSAs), involving the illicit use of medicine, has been recently increasing in Japan. Tirazolam is the most frequently used date-rape drug in DFSAs occurring in Japan. In this study, the effect of triazolam on behavior in response to fear and anxiety was evaluated using an elevated plus-maze test in mice. Triazolam-treated animals (0.01 mg/kg) showed no significant difference in total locomotor activity compared with vehicle-treated mice (controls). On the contrary, activity levels on the open arms of the apparatus (time spent, mean value of movement), where mice would normally feel anxiety or fear, were significantly increased in triazolam-treated mice compared with controls. However, total locomotor activities on the plus-maze were not different between two groups, indicating that sedation was not induced by tirazolam under these conditions. These results suggest that triazolam treatment led the mice to become insensitive to fear and anxiety; their defence reactions were impaired. We conclude that this finding provides scientific evidence in reply to defence arguments presented in court trials that there is little or no evidence of the victim attempting to escape from a sexual assault. Additionally, the finding is as true of other benzodiazepine receptor agonists as of triazolam.
    Jul. 2016, Journal of Forensic Psychology, 1(2) (2), 1 - 4
    [Refereed]
    Scientific journal

  • Hiroki Yoshimatsu, Atsushi Yonezawa, Kaori Yamanishi, Yoshiaki Yao, Kumiko Sugano, Shunsaku Nakagawa, Satoshi Imai, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Satohiro Masuda, Ken-ichi Inui, Kazuo Matsubara
    Jun. 2016, SCIENTIFIC REPORTS, 6, 27557, English
    [Refereed]
    Scientific journal

  • Masaru Asari, Katsuhiro Okuda, Chisato Hoshina, Tomohiro Omura, Yoshikazu Tasaki, Hiroshi Shiono, Kazuo Matsubara, Keiko Shimizu
    Feb. 2016, ANALYTICAL BIOCHEMISTRY, 494, 16 - 22, English
    [Refereed]
    Scientific journal

  • Atsushi Yonezawa, Moto Kajiwara, Ikuko Minami, Tomohiro Omura, Shunsaku Nakagawa, Kazuo Matsubara
    Aug. 2015, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 135(8) (8), 943 - 947, Japanese
    [Refereed]

  • Satoshi Koyama, Tomohiro Omura, Atsushi Yonezawa, Satoshi Imai, Shunsaku Nakagawa, Takayuki Nakagawa, Ikuko Yano, Kazuo Matsubara
    Aug. 2015, PLOS ONE, 10(8) (8), e0136176, English
    [Refereed]
    Scientific journal

  • Masaru Asari, Katsuhiro Okuda, Daisuke Yajima, Chikatoshi Maseda, Chisato Hoshina, Tomohiro Omura, Hiroshi Shiono, Kazuo Matsubara, Keiko Shimizu
    Apr. 2015, JOURNAL OF FORENSIC AND LEGAL MEDICINE, 31, 36 - 41, English
    [Refereed]
    Scientific journal

  • Shunsaku Nakagawa, Tomohiro Omura, Atsushi Yonezawa, Ikuko Yano, Takayuki Nakagawa, Kazuo Matsubara
    Dec. 2014, AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 307(12) (12), F1404 - F1411, English
    [Refereed]
    Scientific journal

  • Miwa Uesugi, Mio Kikuchi, Haruka Shinke, Tomohiro Omura, Atsushi Yonezawa, Kazuo Matsubara, Yasuhiro Fujimoto, Shinya Okamoto, Toshimi Kaido, Shinji Uemoto, Satohiro Masuda
    Jul. 2014, PHARMACOGENETICS AND GENOMICS, 24(7) (7), 356 - 366, English
    [Refereed]
    Scientific journal

  • 杉本 充弘, 米澤 淳, 蓼原 昌美, 森田 洋亮, 吉田 優子, 尾上 雅英, 大村 友博, 萱野 勇一郎, 深津 祥央, 矢野 育子, 松原 和夫
    (一社)日本医療薬学会, May 2014, 医療薬学, 40(5) (5), 297 - 303, Japanese
    [Refereed]

  • Hashi S, Masuda S, Kikuchi M, Uesugi M, Yano I, Omura T, Yonezawa A, Fujimoto Y, Ogawa K, Kaido T, Uemoto S, Matsubara K
    Apr. 2014, Transplant Proc., 71(1) (1), 51 - 58, English
    [Refereed]

  • Mio Kikuchi, Yuki Okuda, Yoshihide Ueda, Yuki Nishioka, Miwa Uesugi, Emina Hashimoto, Tamotsu Takahashi, Tomoki Kawai, Sachiyo Hashi, Haruka Shinke, Tomohiro Omura, Atsushi Yonezawa, Takashi Ito, Yasuhiro Fujimoto, Toshimi Kaido, Tsutomu Chiba, Shinji Uemoto, Kazuo Matsubara, Satohiro Masuda
    Mar. 2014, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37(3) (3), 417 - 423, English
    [Refereed]
    Scientific journal

  • Kumiko Oka, Masaru Asari, Tomohiro Omura, Masatsugu Yoshida, Chikatoshi Maseda, Daisuke Yajima, Kazuo Matsubara, Hiroshi Shiono, Mitsuyoshi Matsuda, Keiko Shimizu
    Feb. 2014, MOLECULAR AND CELLULAR PROBES, 28(1) (1), 13 - 18, English
    [Refereed]
    Scientific journal

  • Hiroki Yoshimatsu, Atsushi Yonezawa, Yoshiaki Yao, Kumiko Sugano, Shunsaku Nakagawa, Tomohiro Omura, Kazuo Matsubara
    Jan. 2014, AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 306(2) (2), G102 - G110, English
    [Refereed]
    Scientific journal

  • Yoshiaki Yao, Atsushi Yonezawa, Hiroki Yoshimatsu, Tomohiro Omura, Satohiro Masuda, Kazuo Matsubara
    Aug. 2013, EUROPEAN JOURNAL OF PHARMACOLOGY, 714(1-3) (1-3), 281 - 287, English
    [Refereed]
    Scientific journal

  • 多座位挿入欠失多型解析に基づく個人識別法の開発
    岡 久美子, 浅利 優, 間瀬田 千香暁, 塩野 寛, 清水 惠子, 松田 光悦, 大村 友博, 松原 和夫, 吉田 将亜
    日本DNA多型学会, May 2013, DNA多型, 21, 214 - 217, Japanese

  • Tomohiro Omura, Masaru Asari, Joe Yamamoto, Kumiko Oka, Chisato Hoshina, Chikatoshi Maseda, Toshio Awaya, Yoshikazu Tasaki, Hiroshi Shiono, Atsushi Yonezawa, Satohiro Masuda, Kazuo Matsubara, Keiko Shimizu
    Mar. 2013, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 432(4) (4), 689 - 694, English
    [Refereed]
    Scientific journal

  • Masaru Asari, Kumiko Oka, Tomohiro Omura, Chikatoshi Maseda, Yoshikazu Tasaki, Hiroshi Shiono, Kazuo Matsubara, Mitsuyoshi Matsuda, Keiko Shimizu
    Feb. 2013, ELECTROPHORESIS, 34(3) (3), 448 - 455, English
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Masayuki Kaneko, Yasunobu Okuma, Kazuo Matsubara, Yasuyuki Nomura
    2013, OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013(239854) (239854), English
    [Refereed]
    Scientific journal

  • 北海道の死因究明制度の将来 フィンランドの死因究明制度に学ぶ
    清水 惠子, 松田 都久美, 北村 麻奈, 吉田 あやか, 浅利 優, 岡 久美子, 間瀬田 千香暁, 大谷 静治, 山田 ひろみ, 保科 千里, 土井 大輝, 大村 友博, 中島 輝夫, 吉田 幸夫, 久田 悟, 松原 和夫, 塩野 寛
    法医学談話会, Nov. 2012, 法医学の実際と研究, (55) (55), 285 - 294, Japanese
    [Refereed]

  • 抗ヒトケラチン抗体を用いた浴槽内溺水診断の検討
    大谷 静治, 浅利 優, 大村 友博, 間瀬田 千香暁, 山田 ひろみ, 保科 千里, 土井 大輝, 松田 都久美, 北村 麻奈, 吉田 あやか, 岡 久美子, 松田 光悦, 塩野 寛, 清水 恵子
    法医学談話会, Nov. 2012, 法医学の実際と研究, (55) (55), 215 - 221, Japanese
    [Refereed]

  • Kazuo Matsubara, Masaru Asari, Manabu Suno, Toshio Awaya, Mitsuru Sugawara, Tomohiro Omura, Joe Yamamoto, Chikatoshi Maseda, Yoshikazu Tasaki, Hiroshi Shiono, Keiko Shimizu
    Jul. 2012, LEGAL MEDICINE, 14(4) (4), 191 - 196, English
    [Refereed]
    Scientific journal

  • Yoshikazu Tasaki, Joe Yamamoto, Tomohiro Omura, Tomoki Sakaguchi, Norihisa Kimura, Ko-ichi Ohtaki, Takashi Ono, Manabu Suno, Masaru Asari, Tomoko Ohkubo, Toshihiro Noda, Toshio Awaya, Keiko Shimizu, Kazuo Matsubara
    Jul. 2012, NEUROSCIENCE LETTERS, 521(1) (1), 15 - 19, English
    [Refereed]
    Scientific journal

  • Masaru Asari, Tomohiro Omura, Kumiko Oka, Chikatoshi Maseda, Yoshikazu Tasaki, Hiroshi Shiono, Kazuo Matsubara, Mitsuyoshi Matsuda, Keiko Shimizu
    Apr. 2012, GENOMICS, 99(4) (4), 227 - 232, English
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Masaru Asari, Joe Yamamoto, Naoya Kamiyama, Kumiko Oka, Chisato Hoshina, Chikatoshi Maseda, Toshio Awaya, Yoshikazu Tasaki, Hiroshi Shiono, Keiko Shimizu, Kazuo Matsubara
    Mar. 2012, JOURNAL OF MOLECULAR NEUROSCIENCE, 46(3) (3), 527 - 535, English
    [Refereed]
    Scientific journal

  • Yoshikazu Tasaki, Joe Yamamoto, Tomohiro Omura, Toshihiro Noda, Naoya Kamiyama, Koichi Yoshida, Machiko Satomi, Tomoki Sakaguchi, Masaru Asari, Tomoko Ohkubo, Keiko Shimizu, Kazuo Matsubara
    Feb. 2012, EUROPEAN JOURNAL OF PHARMACOLOGY, 676(1-3) (1-3), 57 - 63, English
    [Refereed]
    Scientific journal

  • 剖検例における尿中ケトン体の試験紙による比較検討
    山田 ひろみ, 間瀬田 千香暁, 浅利 優, 大村 友博, 岡 久美子, 吉田 あやか, 大谷 静治, 塩野 寛, 松原 和夫, 清水 惠子
    法医学談話会, Nov. 2011, 法医学の実際と研究, (54) (54), 11 - 16, Japanese
    [Refereed]

  • 頭蓋骨からの帰属集団判定 Fordisc 3.0の法医実務への応用
    岡 久美子, 坂上 和弘, 浅利 優, 大村 友博, 吉田 将亜, 間瀬田 千香暁, 松原 和夫, 塩野 寛, 松田 光悦, 清水 惠子
    法医学談話会, Nov. 2011, 法医学の実際と研究, (54) (54), 17 - 23, Japanese
    [Refereed]

  • 法科学的鑑定 アリル特異的伸長反応による微量DNAからのABO式血液型判定
    浅利 優, 岡 久美子, 大村 友博, 間瀬田 千香暁, 塩野 寛, 清水 惠子, 松原 和夫, 松田 光悦
    日本DNA多型学会, May 2011, DNA多型, 19, 205 - 209, Japanese

  • Masaru Asari, Tomohiro Omura, Chikatoshi Maseda, Hiroshi Shiono, Yoshikazu Tasaki, Kazuo Matsubara, Keiko Shimizu
    Dec. 2010, MOLECULAR AND CELLULAR PROBES, 24(6) (6), 381 - 386, English
    [Refereed]
    Scientific journal

  • Masaru Asari, Tomohiro Omura, Chikatoshi Maseda, Kazuo Matsubara, Hiroshi Shiono, Keiko Shimizu
    Nov. 2010, JOURNAL OF FORENSIC SCIENCES, 55(6) (6), 1576 - 1581, English
    [Refereed]
    Scientific journal

  • 麻下 智加, 田崎 嘉一, 大村 友博, 飯田 慎也, 山本 譲, 都築 仁美, 井上 正朝, 大滝 康一, 粟屋 敏雄, 三好 敏之, 間瀬田 千香暁, 清水 惠子, 松原 和夫
    (一社)日本医療薬学会, Aug. 2010, 医療薬学, 36(8) (8), 575 - 579, Japanese
    [Refereed]

  • Yoshikazu Tasaki, Tomohiro Omura, Takehiro Yamada, Tomoko Ohkubo, Manabu Suno, Shinya Iida, Tomoki Sakaguchi, Masaru Asari, Keiko Shimizu, Kazuo Matsubara
    Jul. 2010, BRAIN RESEARCH, 1344, 25 - 33, English
    [Refereed]
    Scientific journal

  • 法医学の新しい社会貢献 旭川市高齢者孤立死防止ガイド作成への取り組み
    清水 惠子, 佐々木 良, 角田 康夫, 小泉 博一, 浅利 優, 大村 友博, 間瀬田 千香暁, 松原 和夫, 塩野 寛
    法医学談話会, Nov. 2009, 法医学の実際と研究, (52) (52), 221 - 226, Japanese
    [Refereed]

  • 大腿骨頭窩の形態を用いた年齢推定法の法医実務における有用性
    山田 ひろみ, 坂上 和弘, 渡邊 智, 浅利 優, 松田 都久美, 大村 友博, 間瀬田 千香暁, 阿久津 弘明, 松原 和夫, 塩野 寛, 清水 惠子
    法医学談話会, Nov. 2009, 法医学の実際と研究, (52) (52), 11 - 16, Japanese
    [Refereed]

  • Toshihiro Noda, Takehiro Yamada, Tomoko Ohkubo, Tomohiro Omura, Takashi Ono, Tomoki Adachi, Toshio Awaya, Yoshikazu Tasaki, Keiko Shimizu, Kazuo Matsubara
    Oct. 2009, JOURNAL OF HEALTH SCIENCE, 55(5) (5), 720 - 725, English
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Masayuki Kaneko, Naoki Tabei, Yasunobu Okuma, Yasuyuki Nomura
    May 2008, JOURNAL OF NEUROSCIENCE RESEARCH, 86(7) (7), 1577 - 1587, English
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Masayuki Kaneko, Masayuki Onoguchi, Shinobu Koizumi, Miho Itarmi, Mariko Ueyama, Yasunobu Okuma, Yasuyuki Nomura
    Mar. 2008, JOURNAL OF PHARMACOLOGICAL SCIENCES, 106(3) (3), 512 - 519, English
    [Refereed]
    Scientific journal

  • Masayuki Kaneko, Saori Yasui, Yoshifumi Niinuma, Kiho Arai, Tomohiro Omura, Yasunobu Okuma, Yasuyuki Nomura
    Nov. 2007, FEBS LETTERS, 581(28) (28), 5355 - 5360, English
    [Refereed]
    Scientific journal

  • Tomohiro Omura, Masayuki Kaneko, Yasunobu Okuma, Yasuko Orba, Kazuo Nagashima, Ryosuke Takahashi, Noboru Fujitani, Satoshi Matsumura, Akihisa Hata, Kyoko Kubota, Karin Murahashi, Takashi Uehara, Yasuyuki Nomura
    Dec. 2006, JOURNAL OF NEUROCHEMISTRY, 99(6) (6), 1456 - 1469, English
    [Refereed]
    Scientific journal

  • K Kubota, Y Niinuma, M Kaneko, Y Okuma, M Sugai, T Omura, M Uesugi, T Uehara, T Hosoi, Y Nomura
    Jun. 2006, JOURNAL OF NEUROCHEMISTRY, 97(5) (5), 1259 - 1268, English
    [Refereed]
    Scientific journal

■ MISC
  • 錠剤同士の接触により生じるテルミサルタン錠の着色とそのメカニズムの解析
    岡崎裕太朗, 大村友博, 上田昌史, 武田紀彦, 竹下治範, 飯田真之, 山本和宏, 土生康司, 宮田興子, 矢野育子
    2024, 医療薬学フォーラム講演要旨集, 32nd

  • 到達度評価シートを用いた薬剤師レジデント制度の運用
    大村 友博
    Lead, May 2023, ファルマシア, 59(5) (5), 408 - 411, Japanese
    [Invited]

  • Search for compounds increasing the expression of ubiquitin ligase HRD1 and suppressing neuronal cell death
    西口大生, 大村友博, 佐登礼佳, 北廣優実, 山本和宏, 國正淳一, 矢野育子
    2023, 日本薬学会年会要旨集(Web), 143rd

  • パーキンソン病発症に関連する小胞体ストレス関連分子SEL1Lを制御するmicroRNAの探索と血漿中microRNA発現量の検討
    西口大生, 大村友博, 大村友博, 野村月渚, 渡邉蘭, 北廣優実, 糸原光太郎, 山本和宏, 國正淳一, 松原和夫, 松原和夫, 矢野育子
    2023, 医療薬学フォーラム講演要旨集, 31st

  • 令和3年度学術委員会学術第2小委員会報告 入退院支援における薬学的介入と患者アウトカムに係る研究
    北田徳昭, 大村友博, 尾上雅英, 佐藤真由美, 柴田ゆうか, 堀内賢一, 宮崎俊明
    Oct. 2022, 日病薬誌, 58(10) (10), 1220 - 1221, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • 和2年度学術委員会学術第3小委員会報告 入退院支援における薬学的介入と患者アウトカムに係る研究
    北田徳昭, 大村友博, 尾上雅英, 佐藤真由美, 柴田ゆうか, 堀内賢一, 宮崎俊明
    Nov. 2021, 日病薬誌, 57(11) (11), 1299 - 1031, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • 薬剤師が主導する非がん疼痛患者へのオピオイド使用状況モニタリングの評価
    飯田真之, 志田有里, 番匠咲帆, 西岡達也, 松沼亮, 坂下明大, 木澤義之, 大村友博, 矢野育子
    2021, 日本緩和医療薬学会年会プログラム・要旨集, 14th

  • オピオイド鎮痛薬使用がん患者への薬剤師による外来電話サポートの介入効果
    志田有里, 飯田真之, 番匠咲帆, 蓼原瞬, 坂下明大, 久米学, 大村友博, 丹生健一, 木澤義之, 矢野育子
    2021, 日本緩和医療薬学会年会プログラム・要旨集, 14th

  • 令和元年度学術委員会学術第5小委員会報告 入退院支援業務における薬学的介入と患者アウトカムに係る研究
    北田徳昭, 大村友博, 尾上雅英, 佐藤真由美, 柴田ゆうか, 堀内賢一, 宮崎俊明
    Oct. 2020, 日病薬誌, 56(10) (10), 1218 - 1222, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • Effects of Hochuekkito on cancer cachexia
    北廣優実, 北廣優実, 山本和宏, 大本暢子, 久米学, 芝野真喜雄, 大村友博, 矢野育子
    2020, 日本薬学会年会要旨集(Web), 140th

  • クロザピン及び活性代謝物の母集団薬物動態解析:入院・外来の影響
    小岸かれん, 小岸かれん, 大村友博, 大村友博, 山本将太, 中川俊作, 米沢淳, 米沢淳, 糸原光太郎, 糸原光太郎, 竹内理人, 竹内理人, 松尾研志, 松尾研志, 橋本凱朝, 橋本凱朝, 諏訪太朗, 佐藤夕紀, 今井哲司, 中川貴之, 村井俊哉, 矢野育子, 矢野育子, 松原和夫
    2019, 日本医療薬学会年会講演要旨集(Web), 29

  • DNA型データベース照合により候補となった身元不明死体の個人識別
    浅利優, 磯崎翔太郎, 奥田勝博, 田中宏樹, 堀岡希衣, 塩野寛, 清水惠子, 大村友博, 松原和夫
    2019, 法医学の実際と研究, 62

  • 非ホジキンリンパ腫患者におけるリツキシマブの体内動態と臨床効果の相関
    大谷祐基, 米澤淳, 森万優子, 磯本唯, 津田真弘, 池見泰明, 今井哲司, 中川俊作, 大村友博, 中川貴之, 北野俊行, 高折晃史, 松原和夫
    Jun. 2018, 医療薬学フォーラム講演要旨集, 26th, 194, Japanese

  • イトラコナゾールを併用した肺移植患者におけるタクロリムス体内動態の経時的変化
    川本雄士, 片田佳希, 中川俊作, 杉本充弘, 糸原光太郎, 山本由貴, 福井彩香, 松田裕也, 松村勝之, 大村友博, 米澤淳, 米澤淳, 中川貴之, 長尾美紀, 陳豊史, 伊達洋至, 松原和夫
    2018, 日本医療薬学会年会講演要旨集(Web), 28

  • マクロファージに着目したHIV誘発末梢神経障害性疼痛の機序解明
    平岩怜, 今井哲司, NTOGWA Mpumelelo, 小柳円花, 佐藤夕紀, 中川俊作, 大村友博, 米澤淳, 中川貴之, 松原和夫
    2018, 鎮痛薬・オピオイドペプチドシンポジウムプログラム・抄録集, 38th, 43, Japanese

  • B細胞リンパ腫患者における、リツキシマブのPK/PD解析
    森 万優子, 米澤 淳, 大谷 祐基, 磯本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 北野 俊行, 高折 晃史, 矢野 育子, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2017, 臨床薬理, 48(Suppl.) (Suppl.), S278 - S278, Japanese

  • B細胞リンパ腫患者における、リツキシマブのPK/PD解析
    森 万優子, 米澤 淳, 大谷 祐基, 磯本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 北野 俊行, 高折 晃史, 矢野 育子, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2017, 臨床薬理, 48(Suppl.) (Suppl.), S278 - S278, Japanese

  • 質量分析法を駆使した最新薬物動態研究 LC/TOF-MSを用いた抗体医薬品の体内動態解析
    大谷 祐基, 米澤 淳, 津田 真弘, 今井 哲司, 池見 泰明, 大村 友博, 中川 俊作, 中川 貴之, 矢野 育子, 松原 和夫
    (一社)日本医用マススペクトル学会, Aug. 2017, JSBMS Letters, 42(Suppl.) (Suppl.), 43 - 43, Japanese

  • リツキシマブの体内動態とその変動因子の考察
    大谷祐基, 米澤淳, 礒本唯, 津田真弘, 池見泰明, 今井哲司, 大村友博, 中川俊作, 中川貴之, 矢野育子, 北野俊行, 高折晃史, 松原和夫
    Jun. 2017, 医療薬学フォーラム講演要旨集, 25th, 233, Japanese

  • 4-フェニル酪酸と抗酸化剤のパラコート毒性に対する細胞保護メカニズムの比較
    大村 友博, 保科 千里, 奥田 勝博, 田中 宏樹, 磯崎 翔太郎, 早川 輝, 浅利 優, 塩野 寛, 松原 和夫, 清水 惠子
    (NPO)日本法医学会, May 2017, 日本法医学雑誌, 71(1) (1), 98 - 98, Japanese

  • 微小管阻害薬によるシュワン細胞の脱分化を伴った脱髄が抗がん剤誘発末梢神経障害の発症に関与する
    松本 真有奈, 今井 哲司, 小柳 円花, 中里 唯, Ziauddin Azimi, 米澤 淳, 大村 友博, 中川 俊作, 金子 周司, 中川 貴之, 松原 和夫
    Mar. 2017, 第90回 日本薬理学会年会

  • 社会的敗北ストレス負荷によるうつ病モデルマウスにおけるブロチゾラム誘発睡眠作用の効力変化に関する行動薬理学的研究
    宮山 大, 今井哲司, 辻 光貴, 重面雄紀, 米澤 淳, 大村友博, 中川俊作, 矢野育子, 中川貴之, 松原和夫
    Jun. 2016, 医療薬学フォーラム2016

  • 社会的敗北ストレス誘発うつ病モデルにおけるブロチゾラム誘発睡眠作用の効力変化
    辻 光貴, 今井 哲司, 宮山 大, 西谷 直也, 米澤 淳, 大村 友博, 中川 俊作, 中川 貴之, 金子 周司, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(3) (3), 165 - 165, Japanese

  • インフリキシマブ先行品と後続品における糖鎖構造の比較
    津田 真弘, 大谷 祐基, 米澤 淳, 池見 泰明, 大村 友博, 中川 俊作, 今井 哲司, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 82 - 82, Japanese

  • 社会的敗北ストレス誘発うつ病モデルにおけるブロチゾラム誘発睡眠作用の効力変化
    辻 光貴, 今井 哲司, 宮山 大, 西谷 直也, 米澤 淳, 大村 友博, 中川 俊作, 中川 貴之, 金子 周司, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(3) (3), 165 - 165, Japanese

  • インフリキシマブ先行品と後続品における糖鎖構造の比較
    津田 真弘, 大谷 祐基, 米澤 淳, 池見 泰明, 大村 友博, 中川 俊作, 今井 哲司, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 82 - 82, Japanese

  • Social defeat モデルにおけるブロチゾラム誘発睡眠作用の効力変化に関する行動薬理学的研究
    辻 光貴, 今井哲司, 宮山 大, 西谷直哉, 米澤 淳, 大村友博, 中川俊作, 中川貴之, 金子周司, 松原和夫
    Mar. 2016, 日本薬学会第136年会

  • 虚血性心筋症に対する新たなオプションとしての血管新生療法の可能性
    KUMAGAI MOTOYUKI, MINAKATA KENJI, YAMAMOTO MASAYA, OMURA TOMOHIRO, YONEZAWA ATSUSHI, SAKAMOTO KAZUHISA, NISHIO HIROOMI, NAKATA TOMOHIRO, UEHARA AKIHIRO, SAKAGUCHI HITOHISA, YAMAZAKI KAZUHIRO, IKEDA TADASHI, MATSUBARA KAZUO, TABATA YASUHIKO, SAKATA RYUZO
    日本バイオマテリアル学会, 09 Nov. 2015, 日本バイオマテリアル学会大会予稿集, 37th, 344 - 344, Japanese

  • 虚血性心筋症に対する新たなオプションとしての血管新生療法の可能性
    熊谷 基之, 南方 謙二, 山本 雅哉, 大村 友博, 米澤 淳, 坂本 和久, 西尾 博臣, 中田 朋宏, 上原 京勲, 阪口 仁寿, 山崎 和裕, 池田 義, 松原 和夫, 田畑 泰彦, 坂田 隆造
    日本バイオマテリアル学会, Nov. 2015, 日本バイオマテリアル学会大会予稿集, 37回, 344 - 344, Japanese

  • 21-7-O13-04 悪性黒色腫に対するニボルマブ治療における免疫関連有害反応の検討(がん薬物療法(副作用対策),口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    山本 将太, 長谷川 真理, 吉良 俊彦, 池見 泰明, 大村 友博, 矢野 育子, 藤澤 章弘, 椛島 健治, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 208 - 208, Japanese

  • 21-8-O19-14 医師と薬剤師が協働する乳癌術後ホルモン治療教室による患者の理解度の変化(がん薬物療法(多職種連携),口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    猪熊 容子, 山本 浩貴, 池見 泰明, 石塚 良子, 深津 祥央, 大村 友博, 中川 俊作, 今井 哲司, 鈴木 栄治, 竹内 恵, 戸井 雅和, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 214 - 214, Japanese

  • 血液・リンパ リンパ腫治療の将来展望 生体内におけるリツキシマブの経時的構造変化の解析
    大谷 祐基, 米澤 淳, 今井 哲司, 津田 真弘, 兼吉 真千子, 池見 泰明, 大村 友博, 中川 俊作, 矢野 育子, 北野 俊行, 高折 晃史, 松原 和夫
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 2082 - 2082, Japanese

  • 薬力学的特徴に基づくシスプラチンの腎毒性発現機序の解明
    CHO INHO, YONEZAWA ATSUSHI, NAKAGAWA SHUNSAKU, NIMURA AKINORI, YOSHIMATSU HIROKI, OMURA TOMOHIRO, IMAI TETSUJI, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    Jun. 2015, 医療薬学フォーラム講演要旨集, 23rd, 304, Japanese

  • リツキシマブの生体内における構造変化の評価
    大谷 祐基, 米澤 淳, 今井 哲司, 津田 真弘, 池見 泰明, 大村 友博, 中川 俊作, 中川 貴之, 松原 和夫
    (公社)日本薬剤学会, May 2015, 日本薬剤学会年会講演要旨集, 30年会, 137 - 137, Japanese

  • EGFR阻害薬による肺障害とeIF2αのリン酸化
    KOYAMA SATOSHI, OMURA TOMOHIRO, NAKAGAWA SHUNSAKU, IMAI TETSUJI, YONEZAWA ATSUSHI, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    (公社)日本薬学会, Mar. 2015, 日本薬学会年会要旨集(CD-ROM), 135th(3) (3), ROMBUNNO.27U-PM04 - 85, Japanese

  • 27-O1PM-04 クロザピンによる副作用の実態調査と薬剤師による介入の効果(副作用(実態調査と対策),優秀演題候補セッション1,新時代を拓く医療薬学フロンティア)
    八田 眞菜美, 重面 雄紀, 山本 将太, 萱野 勇一郎, 大村 友博, 矢野 育子, 諏訪 太朗, 村井 俊哉, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 175 - 175, Japanese

  • 27-O3PM-07 トレーシングレポート(服薬情報提供書)を利用した病診薬連携の推進(薬薬連携、その他,優秀演題候補セッション6,新時代を拓く医療薬学フロンティア)
    礒本 唯, 萱野 勇一郎, 池見 泰明, 杉本 充弘, 大村 友博, 米澤 淳, 深津 祥央, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 189 - 189, Japanese

  • LC/TOF‐MSを用いた抗体医薬品の糖鎖解析
    OTANI YUKI, MATSUMURA KENGO, YONEZAWA ATSUSHI, OMURA TOMOHIRO, TSUDA MASAHIRO, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24th, 420, Japanese

  • LC/TOF‐MSによるG‐CSFバイオ後続品の定性分析
    MATSUMURA KENGO, OTANI YUKI, OMURA TOMOHIRO, YONEZAWA ATSUSHI, TSUDA MASAHIRO, YOSHIKI TATSUHIRO, MATSUBARA KAZUO
    25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24th, 420, Japanese

  • RFVT3ノックアウトマウスにおけるリボフラビン恒常性の破綻
    吉松宏樹, 米澤淳, 山西香里, 八尾祉顕, 中川俊作, 大村友博, 松原和夫
    (公社)日本薬学会, Mar. 2014, 日本薬学会年会要旨集(CD-ROM), 134th(4) (4), ROMBUNNO.29V-PM06S - 84, Japanese

  • 治験薬GMP基準の院内製剤製造によるトランスレーショナルリサーチへの貢献
    米澤淳, 梶原望渡, 南いく子, 大村友博, 中川俊作, 松原和夫
    2014, 日本薬学会年会要旨集(CD-ROM), 134th, ROMBUNNO.S31-3, Japanese

  • 北海道沿岸における珪藻分布の解析報告(第三報)
    毎熊 浩二, 浅利 優, 山田 ひろみ, 松田 都久美, 岡 久美子, 北村 麻奈, 吉田 あやか, 土井 大輝, 保科 千里, 大谷 静治, 間瀬田 千香暁, 塩野 寛, 清水 惠子, 大村 友博, 早川 輝, 村上 学, 的場 光太郎, 寺沢 浩一, 山田 直弥, 中村 一, 阿部 祐亮, 三和 正人, 吉田 幸夫
    法医学談話会, Nov. 2013, 法医学の実際と研究, (56) (56), 266 - 266, Japanese

  • パラコート誘発細胞死におけるユビキチンリガーゼHRD1,Parkinの役割とケミカルシャペロンによる細胞死抑制効果の検討
    大村友博, 山本譲, 浅利優, 岡久美子, 保科千里, 米澤淳, 増田智先, 粟屋敏雄, 田崎嘉一, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    (株)へるす出版, 10 Sep. 2013, 中毒研究, 26(3) (3), 265 - 265, Japanese

  • メロキシカムは，マウスパーキンソン病モデルにおいて，Aktシグナル維持により運動障害とドパミン神経変性を改善する
    田崎嘉一, 山本譲, 大村友博, 坂口智己, 木村周古, 大滝康一, 小野尚志, 須野学, 浅利優, 大久保知子, 野田敏宏, 粟屋敏雄, 清水惠子, 松原和夫
    Aug. 2013, 北海道医学雑誌, 88(1) (1), Japanese
    [Invited]
    Introduction scientific journal

  • EGFR阻害薬の毒性発現と小胞体ストレスの関与
    小山智志, 大村友博, 笹岡美和, 米澤淳, 福土将秀, 増田智先, 松原和夫
    Jul. 2013, 医療薬学フォーラム講演要旨集, 21st, 231, Japanese

  • 薬物性腎障害とトランスポータ機能との関連
    増田智先, 米澤淳, 大村友博, 松原和夫
    05 Jun. 2013, 日本DDS学会学術集会プログラム予稿集, 29th, 110, Japanese

  • パラコート毒性における小胞体ストレスの関与とケミカルシャペロンによる細胞死抑制効果
    大村友博, 浅利優, 岡久美子, 保科千里, 米澤淳, 増田智先, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    (NPO)日本法医学会, 20 May 2013, 日本法医学雑誌, 67(1) (1), 89 - 89, Japanese

  • Real‐time PCRを用いたCYP3A5及びCYP2C19の遺伝子多型迅速判定法の開発と生体肝移植におけるタクロリムスTDM業務への応用
    山本譲, 大村友博, 田崎嘉一, 浅利優, 岡久美子, 米澤淳, 増田智先, 粟屋敏雄, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    (公社)日本薬学会, Mar. 2013, 日本薬学会年会要旨集(CD-ROM), 133rd(4) (4), ROMBUNNO.29AMF-313 - 141, Japanese

  • メロキシカムは, マウスパーキンソン病モデルにおいて, Aktシグナル維持により運動障害とドパミン神経変性を改善する
    田崎 嘉一, 山本 譲, 大村 友博, 坂口 智己, 木村 周古, 大滝 康一, 小野 尚志, 須野 学, 浅利 優, 大久保 知子, 野田 敏宏, 粟屋 敏雄, 清水 惠子, 松原 和夫
    01 Jan. 2013, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 88(1) (1), Japanese

  • HRD1 Levels Increased by Zonisamide Prevented Cell Death and Caspase-3 Activation Caused by Endoplasmic Reticulum Stress in SH-SY5Y Cells
    大村 友博, 浅利 優, 山本 譲, 神山 直也, 岡 久美子, 保科 千里, 間瀬田 千香暁, 粟屋 敏雄, 田崎 嘉一, 塩野 寛, 清水 惠子, 松原 和夫
    01 Nov. 2012, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87(6) (6), 251 - 251, Japanese
    [Invited]
    Introduction scientific journal

  • 薬剤師業務の専門性と心がまえ
    大村友博, 松原和夫
    May 2012, 月間薬事, Japanese
    [Invited]
    Introduction commerce magazine

  • 薬剤師業務の専門性と心がまえ (特集 先輩が教える 薬剤師業務のノウハウとピットフォール)
    大村 友博, 松原 和夫
    じほう, May 2012, 月刊薬事, 54(5) (5), 713 - 715, Japanese

  • Enhanced discrimination of single nucleotide polymorphisms using 3' nucleotide differences in ligase detection reaction probes
    浅利 優, 大村 友博, 間瀬田 千香暁, 塩野 寛, 田崎 嘉一, 松原 和夫, 清水 惠子
    01 Apr. 2012, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87(2-3) (2-3), 67 - 67, Japanese
    [Invited]
    Introduction scientific journal

  • ユビキチンリガーゼの活性化によるパーキンソン病治療法の確立
    大村 友博
    雑誌掲載版
    Feb. 2012, 旭川医科大学研究フォーラム, 12(1) (1), 70 - 70, Japanese
    [Invited]
    Introduction research institution

  • パラコート毒性における小胞体ストレス応答分子の関与とケミカルシャペロンによる細胞保護効果の検討
    大村友博, 大村友博, 浅利優, 山本譲, 神山直也, 岡久美子, 保科千里, 粟屋敏雄, 田崎嘉一, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    2012, 日本薬学会年会要旨集, 132nd(3) (3)

  • TDMオーダリングシステムおよび臨床検査情報システムを統合したハイブリッドTDMシステムの構築
    山本譲, 大村友博, 大村友博, 神山直也, 山田峻史, 田原克寿, 都築仁美, 粟屋敏雄, 大滝康一, 大滝康一, 田崎嘉一, 松原和夫
    2011, 医療薬学フォーラム講演要旨集, 19th

  • LC/MS/MSを用いた小児肺動脈性肺高血圧患者血中ボセンタンTDM
    神山直也, 田崎嘉一, 大村友博, 小城香緒里, 田原克寿, 山本譲, 太田圭, 杉本昌也, 梶濱あや, 梶野浩樹, 松原和夫
    2011, 医療薬学フォーラム講演要旨集, 19th

  • オキシカム系NSAIDsによる神経細胞死抑制作用はAkt/mTOR経路を介する
    田崎嘉一, 山本譲, 大久保知子, 須野学, 大村友博, 神山直也, 吉田光一, 野田敏宏, 坂口智己, 松原和夫
    2011, 日本薬学会年会要旨集, 131st(4) (4)

  • Clostridium difficile感染症の再発に対する新たなモノクローナル抗体治療(F・医療薬科学)
    大村 友博
    公益社団法人 日本薬学会, 2010, ファルマシア, 46(9) (9), 894 - 895, Japanese

  • HRD1 has other functions besides ubiquitin ligase activity
    Tomohiro Omura, Masayuki Kaneko, Masayuki Onoguchi, Yasuyuki Nomura, Yasunobu Okuma
    2009, JOURNAL OF PHARMACOLOGICAL SCIENCES, 109, 289P - 289P, English
    Summary international conference

  • Suppression of HRD1 expression induces APP accumulation causing ER stress and apoptosis
    Masayuki Kaneko, Hiroshi Koike, Tomohiro Omura, Yasunobu Okuma, Yasuyuki Nomura
    2008, JOURNAL OF PHARMACOLOGICAL SCIENCES, 106, 51P - 51P, English
    Summary international conference

  • A ubiquitin ligase HRD1, involved in ERAD, promotes the degradation of Pael-R, a substrate of Parkin
    Tomohiro Omura, Masayuki Kaneko, Yasunobu Okuma, Yasuyuki Nomura
    2007, JOURNAL OF PHARMACOLOGICAL SCIENCES, 103, 183P - 183P, English
    Summary international conference

■ Books And Other Publications
  • 到達度評価シートを用いた薬剤師レジデント制度の運用
    大村友博
    ファルマシア, May 2023

  • 外来でよくみる29疾患の最新ガイドライン虎の巻
    大村友博
    Contributor, 第5章 神経疾患 パーキンソン病, じほう, Oct. 2022

  • 薬にまつわる疑問に答える
    大村友博, 矢野育子
    Contributor, 「薬剤の投与法とそれによる差について教えてください」, 出版社東京医学社, Sep. 2022

  • お薬立ち BOOK 2022
    中西悦郎, 高橋良輔, 大村友博, 松原和夫
    Contributor, 精神神経系（脳神経内科疾患） 18．パーキンソン病, 薬局73巻4号（南山堂）, Mar. 2022

  • できる薬剤師とよばれるために 上手に使いたい薬学ナレッジ101
    Contributor, p114-p122, p195-p198, じほう, Dec. 2021

  • 病気とくすり2021 基礎と実践Expert's Guide.
    中西悦郎, 高橋良輔, 大村友博, 松原和夫
    Contributor, 1．精神・神経系の病気とくすり B 中枢系疾患 パーキンソン病), 薬局72巻4号（南山堂）, Mar. 2021

  • 病気とくすり2020 基礎と実践Expert's Guide.
    中西悦郎, 高橋良輔, 大村友博, 松原和夫
    Contributor, 2．精神・中枢神経系の病気とくすり 中枢系疾患 パーキンソン病, 薬局71巻4号（南山堂）, Apr. 2020

  • 地域包括ケアで薬立つ 4 ELEMENTS実践ガイド
    Contributor, 1st Element 処方箋検査値，4-8～4-10, Feb. 2020

  • 薬剤師のための疾患別薬物療法Ⅱ 精神・脳神経疾患／消化器疾患 改訂第2版
    大村友博, 松原和夫
    Contributor, A 精神・脳神経系疾患 第3章．パーキンソン病, 南江堂, Mar. 2018

  • 病気とくすり2018 基礎と実践Expert’s Guide
    大村友博, 松原和夫
    Contributor, 2. 精神・神経系の病気とくすり パーキンソン病, 南山堂, Mar. 2018

  • 病気とくすり2017 基礎と実践Expert’s Guide
    大村友博, 松原和夫
    Contributor, １．精神・神経系の病気と薬 B．中枢系疾患 パーキンソン病, 南山堂, Mar. 2017

  • 病気とくすり2016 基礎と実践Expert’s Guide
    大村友博, 松原和夫
    Contributor, １．精神・神経系の病気と薬 B．中枢系疾患 パーキンソン病, 南山堂, Mar. 2016

  • 薬剤師のための疾患別薬物療法Ⅱ．精神・脳神経疾患／消化器疾患
    大村友博, 松原和夫
    Contributor, A）精神・脳神経系疾患 3章．パーキンソン病, 南江堂, 2011

■ Lectures, oral presentations, etc.
  • パーキンソン病モデルにおける細胞死を抑制する化合物の探索とメカニズム解明
    兼田遥花, 大村友博, 木村祐美子, 吉井花緒, 北廣優実, 糸原光太郎, 上田昌史, 白木孝, 矢野育子
    医療薬学フォーラム2025／第33回クリニカルファーマシーシンポジウム, Jun. 2025, Japanese
    Poster presentation

  • リトドリン注射製剤による痒疹発現と原因物質の探索
    玉村麻有, 橋本真梨, 山本和宏, 藤原尚子, 今福仁美, 北廣優実, 大村友博, 篠原正和, 上田昌史, 矢野育子
    医療薬学フォーラム2025／第33回クリニカルファーマシーシンポジウム, Jun. 2025, Japanese
    Poster presentation

  • MICRORNA REGULATING SEL1L INVOLVED IN THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS EXPRESSION LEVELS IN PATIENT PLASMA
    Omura T., Nomura L., Nishiguchi H., Kaneda H., Kitahiro Y., Itohara K., Tanaka A., Furubayashi T., Yamamoto K., Sakane T., Matsubara K., Yano I.
    American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2025 Annual Meeting, May 2025, English
    Poster presentation

  • PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL ANALYSIS OF ANTIPSYCHOTICS BEFORE AND AFTER CHILDBIRTH
    Itohara K., Fujita K., Kitahiro Y., Fujiwara N., Konishi T., Hashimoto M., Yamamoto K., Omura T., Yano I.
    American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2025 Annual Meeting, May 2025, English
    Poster presentation

  • フルオロウラシルによるメラニン産生を抑制する化合物の探索
    野網万那, 北廣優実, 糸原光太郎, 大村友博, 矢野育子
    日本薬学会第145年会, Mar. 2025, Japanese
    Poster presentation

  • オシメルチニブによる間質性肺疾患のin vitroモデルの作製と評価
    高橋大, 山本和宏, 太田かなる, 北廣優実, 糸原光太郎, 大村友博, 矢野育子
    日本薬学会第145年会, Mar. 2025, Japanese
    Poster presentation

  • 調剤自動化システムおよびピッキングサポート導入がもたらす調剤過誤および疑義照会の変化
    辻屋徳恵, 山本和宏, 丸川千佳, 飯田真之, 谷藤亜希子, 野崎晃, 宇田篤史, 大村友博, 矢野育子
    第46回日本病院薬剤師会近畿学術大会, Jan. 2025, Japanese
    Oral presentation

  • 糖尿病併発がん患者のベバシズマブ誘発蛋白尿発現に対するインクレチン関連薬の増悪抑制効果の検討：多機関後方視的コホート研究
    高田麻季, 山本和宏, 堀智貴, 生島繁樹, 真野優利花, 丹田雅明, 大村友博, 矢野育子
    第34回日本医療薬学会年会, Nov. 2024, Japanese
    Oral presentation

  • 医療連携による外来レンバチニブ療法のテレフォンフォローアップ体制の効果
    森岡朝美, 山本和宏, 榎本大智, 小松昇平, 大村友博, 矢野育子
    第34回日本医療薬学会年会, Nov. 2024, Japanese
    Oral presentation

  • 外来がん薬物療法におけるトレーシングレポートを介した保険薬局の薬学的介入とその効果
    津田瑞季, 丹田雅明, 伊藤雄大, 飯田真之, 大本暢子, 山本和宏, 大村友博, 矢野育子
    第34回日本医療薬学会年会, Nov. 2024, Japanese
    Oral presentation

  • ベバシズマブ投与における血圧変動因子の探索
    中﨑帆南, 倉岡李圭, 大川恭子, 田内義彦, 濱宏仁, 辻本勉, 大村友博, 矢野育子, 桒原晶子
    第74回日本薬学会関西支部総会・大会, Oct. 2024, Japanese
    Poster presentation

  • 錠剤同士の接触により生じるテルミサルタン錠の着色とそのメカニズムの解析
    岡崎裕太朗, 大村友博, 上田昌史, 武田紀彦, 竹下治範, 飯田真之, 山本和宏, 土生康司, 宮田興子, 矢野育子
    医療薬学フォーラム2024／第32回クリニカルファーマシーシンポジウム, Jul. 2024, Japanese
    Poster presentation

  • Calvert式に用いる腎機能指標とカルボプラチンによる血液毒性発現の関連
    小林理乃, 山本和宏, 丹田雅明, 糸原光太郎, 北廣優実, 大村友博, 矢野育子
    第40回日本TDM学会・学術大会, Jul. 2024, Japanese
    Oral presentation

  • ニルマトレルビル/リトナビル適正使用に向けた体制の構築とその評価
    松本由季, 木村丈司, 冨田猛, 宇田篤史, 山本和宏, 大村友博, 矢野育子
    日本薬学会第144年会, Mar. 2024, Japanese
    Oral presentation

  • 術後悪心嘔吐発生率に対する薬剤師介入の効果
    住吉霞美, 栗村朋子, 山下和彦, 村川亜光, 津田瑞季, 田口真也, 山本和宏, 大村友博, 矢野育子
    第45回日本病院薬剤師会近畿学術大会, Jan. 2024, Japanese
    Poster presentation

  • ブレクスピプラゾール、クエチアピンおよびリスペリドンを服用中の妊婦とその児における薬物動態の評価
    小西徹, 北廣優実, 藤原尚子, 山本和宏, 糸原光太郎, 藤岡一路, 今福仁美, 大塚郁夫, 大村友博, 矢野育子
    第45回日本病院薬剤師会近畿学術大会, Jan. 2024, Japanese
    Poster presentation

  • Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-positive non-small cell lung cancer
    Hori T, Yamamoto K, Ito T, Ikushima S, Itohara K, Kitahiro Y, Omura T, Yano I
    第33回日本医療薬学会年会, Nov. 2023, Japanese
    Oral presentation

  • 薬剤師外来が抗血栓薬服用患者の長期臨床アウトカムに与える影響
    栗村朋子, 山本和宏, 田中秀和, 鳥羽敬義, 木村丈司, 土生康司, 糸原光太郎, 北廣優実, 大村友博, 矢野育子
    第33回日本医療薬学会年会, Nov. 2023, Japanese
    Oral presentation

  • 先天性サイトメガロイウルス感染症患者におけるガンシクロビルのPK/PD解析
    糸原光太郎, 藤中俊輔, 山本和宏, 橋本真梨, 田村直暉, 北廣優実, 大村友博, 藤岡一路, 矢野育子
    第33回日本医療薬学会年会, Nov. 2023, Japanese
    Oral presentation

  • A model-based pharmacokinetic analysis of drug-drug interaction between nirmatrelvir/ritonavir and tacrolimus
    Itohara K, Tomida T, Yamamoto K, Kimura T, Fujita K, Uda A, Kitahiro Y, Yokoyama N, Hyodo Y, Omura T, Yano I
    21st International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Sep. 2023, English
    Poster presentation

  • パーキンソン病発症に関連する小胞体ストレス関連分子SEL1Lを制御するmicroRNAの探索と血漿中microRNA発現量の検討
    西口大生, 大村友博, 野村月渚, 渡邉蘭, 北廣優実, 糸原光太郎, 山本和宏, 國正淳一, 松原和夫, 矢野育子
    医療薬学フォーラム2023／第31回クリニカルファーマシーシンポジウム, Jul. 2023, English

  • 非がん性疼痛に対して使用されるオピオイド性鎮痛薬の薬剤師による使用状況モニタリングとその効果
    飯田真之, 志田有里, 番匠咲帆, 大本暢子, 山下和彦, 槇本博雄, 山本和宏, 大村友博, 矢野育子
    10. 第16回日本緩和医療薬学会学術大会, May 2023, Japanese
    Oral presentation

  • ユビキチンリガーゼHRD1を誘導する化合物の探索と神経細胞死抑制効果の検討
    西口大生, 大村友博, 佐登礼佳, 北廣優実, 山本和宏, 國正淳一, 矢野 育子
    日本薬学会第143年会, Mar. 2023, Japanese
    Oral presentation

  • 非小細胞肺がん患者におけるオシメルチニブの有害事象に関する薬理遺伝学的解析
    丹田雅明, 山本和宏, 堀智貴, 西口大生, 八木美樹, 清水倫子, 小西徹, 尾崎智規, 吉岡奈津恵, 立原素子, 伊藤武文, 生島繁樹, 大村友博, 矢野育子
    日本薬学会第143年会, Mar. 2023, Japanese
    Oral presentation

  • 免疫チェックポイント阻害薬投与患者の好中球リンパ球比による層別化とプロトンポンプ阻害薬の併用による生命予後への影響
    堀智貴, 山本和宏, 伊藤武文, 生島繁樹, 大村友博, 矢野育子
    日本臨床腫瘍薬学会学術大会2023, Mar. 2023, Japanese
    Oral presentation

  • 潜在的不適切処方の中止維持における退院時薬剤情報提供の有用性
    古江由依, 山本和宏, 木村丈司, 高橋知子, 大本暢子, 槇本博雄, 大村友博, 坂根稔康, 國正淳一, 矢野育子
    第44日本病院薬剤師会近畿学術大会（近畿薬剤師合同学術大会2023）, Feb. 2023, Japanese
    Oral presentation

  • Mir-101 regulates neuronal cell death by targeting suppressor/enhancer lin-12-like (SEL1L) in a cellular model of Parkinson’s disease using 6-hydorxydopamine
    Omura T, Nomura L, Nishiguchi H, Yamamoto K, Imai S, Nakagawa S, Itohara K, Yonezawa A, Nakagawa T, Yano I, Matsubara K
    Neuroscience 2022, Nov. 2022, English
    Poster presentation

  • 分子標的型抗がん薬による間質性肺疾患発症の分子機構に基づく予測法の開発－mTOR阻害薬による間質性肺疾患とSTAT3の関連－
    山本和宏, 吉田彩夏, 大村友博, 矢野育子
    第72回日本薬学会関西支部総会・大会, Oct. 2022, Japanese
    Oral presentation

  • ニルマトレルビル/リトナビルの適正使用に向けた予備的検討
    冨田 猛, 木村丈司, 山本和宏, 野崎晃, 田村直暉, 藤田浩平, 飯田真之, 大村友博, 矢野育子
    第32回日本医療薬学会年会, Sep. 2022, Japanese
    Poster presentation

  • Effects of long-term multiple immunosuppressants on everolimus pharmacokinetics in patients after renal transplantation
    Sakaue T, Yamamoto K, Endo T, Ishimura T, Fujisawa M, Omura T, Yano I
    第32回日本医療薬学会年会, Sep. 2022, English
    Poster presentation

  • ユビキチンリガーゼHRD1を制御するマイクロRNAの探索とパーキンソン病との関連
    西口大生, 大村友博, 山本和宏, 矢野育子
    医療薬学フォーラム2022／第30回クリニカルファーマシーシンポジウム, Jul. 2022, Japanese
    Poster presentation

  • スニチニブ投与ラットを用いた手足皮膚反応の原因角化因子の探索とヒト表皮角化細胞株による検証
    中嶋木の実, 山本和宏, 坂根稔康, 藤川実加, 大村友博, 矢野育子
    医療薬学フォーラム2022／第30回クリニカルファーマシーシンポジウム, Jul. 2022, Japanese
    Poster presentation

  • 抗菌薬のTDMにおけるプレアボイド事例と入院期間に及ぼす影響
    田村直暉, 山本和宏, 阪上倫行, 木村丈司, 大村友博, 矢野育子
    第38回日本TDM学会・学術大会, May 2022, Japanese
    Poster presentation

  • カルボプラチンによる血液毒性の発現と投与量算出のための腎機能推算法の関連
    松下すみれ, 山本和宏, 丹田雅明, 國正淳一, 大村友博, 矢野育子
    日本薬学会第142年会, Mar. 2022, Japanese
    Poster presentation

  • がん化学療法誘発性悪心・嘔吐の予防を目的としたオランザピンの低用量投与と傾眠発現との関連
    穐原裕奈, 山本和宏, 水田直美, 丹田雅明, 伊藤雄大, 大村友博, 坂根稔康, 國正淳一, 矢野育子
    第43回日本病院薬剤師会近畿学術大会, Jan. 2022
    Oral presentation

  • Sequential Therapy from 1st or 2nd Generation EGFR-TKI to Osimertinib Lead to the Better Prognosis Compared to Prior Osimertinib therapy for Japanese Non-Small Cell Lung Cancer Patients with Exon 19 Deletions
    Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I
    The 5th International Cancer Research Symposium, Jan. 2022, English
    Poster presentation

  • 2型糖尿病教育入院患者における注射薬導入によるDTR-QOLの変化に関する検討
    菅生有夏, 松本久美子, 谷藤亜希子, 山本和宏, 大本暢子, 松田季代子, 高田綾子, 村前直和, 廣田勇士, 大村友博, 矢野育子
    第58回日本糖尿病学会近畿地方会, Oct. 2021, Japanese

  • 腎癌患者におけるスニチニブの薬物動態に関するモデル解析
    伊藤雄大, 山本和宏, 大村友博, 矢野育子
    第31回日本医療薬学会年会, Oct. 2021, Japanese
    Public symposium

  • スニチニブを内服する腎細胞癌患者を対象とした手足皮膚反応の予防に対するAmitose-DGA含有クリームの第I/II相試験（DGA-study）
    山本和宏, 西山智司, 国定充, 五百蔵武士, 飯田真之, 伊藤雄大, 槇本博雄, 大村友博, 原田健一, 藤澤正人, 錦織千佳子, 矢野育子
    第31回日本医療薬学会年会, Oct. 2021, Japanese
    Oral presentation

  • 一包化錠剤仕分装置（TABSORT）使用に伴うテルミサルタン錠の変色とその要因
    岡崎裕太朗, 竹下治範, 藤澤諒子, 山下和彦, 山本和宏, 槇本博雄, 大村友博, 國正淳一, 矢野育子
    第31回日本医療薬学会年会, Oct. 2021, Japanese
    Poster presentation

  • ペムブロリズマブ療法を受けた転移性または切除不能尿路上皮がん患者に対するプロトンポンプ阻害薬の投与が生命予後に及ぼす影響
    國光葉子, 森尾佳代子, 平田佐智, 山本和宏, 大村友博, 原琢人, 原田健一, 藤澤正人, 矢野育子
    第31回日本医療薬学会年会, Oct. 2021, Japanese
    Poster presentation

  • 薬剤師レジデント研修に対するルーブリック評価の導入効果
    綿本有希子, 伊藤雄大, 清水倫子, 栗村朋子, 松本久美子, 谷藤亜希子, 飯田真之, 大本暢子, 久米学, 山本和宏, 大村友博, 矢野育子
    第31回日本医療薬学会年会, Oct. 2021, Japanese
    Poster presentation

  • Clinical significance of therapeutic drug monitoring of sunitinib in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule
    Ito T, Yamamoto K, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I
    第31回日本医療薬学会年会, Oct. 2021, English
    Oral presentation

  • Development of a physiologically based pharmacokinetic model of fentanyl for preventing central toxicity in neonate patients on respiratory support
    Walaa Mahdy, Yamamoto K, Joji R, Hashimoto M, Nakasone R, Fujioka K, Omura T, Yano I.
    The 18th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2021), Sep. 2021, English
    Poster presentation

  • Association of serum fentanyl concentration and oxygen desaturation with oversedation in neonates
    Yamamoto K, Joji R, Hashimoto M, Walaa Mahdy, Nakasone R, Fujioka K, Omura T, Yano I
    The 18th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2021), Sep. 2021, English
    Poster presentation

  • ブレクスピプラゾール服用妊婦における母児血漿中濃度および母乳中濃度解析を行った1例
    藤原尚子, 伊藤雄大, 小西徹, 橋本真梨, 山本和宏, 藤岡一路, 今福仁美, 蓬莱政, 青山慎介, 大村友博, 矢野育子
    医療薬学フォーラム2021／第29回クリニカルファーマシーシンポジウム, Jul. 2021, Japanese
    Poster presentation

  • Development of Physiologically Based Pharmacokinetic Model of Risperidone and Extrapolation to Different Ethnic Groups and Special Population
    Walaa Mahdy, Kazuhiro Yamamoto, Tomohiro Omura, Ikuko Yano
    The CSPS/PSJ/CC-CRS 2021 Symposium, Jun. 2021, English
    Poster presentation

  • 薬剤師が主導する非がん疼痛患者へのオピオイド使用状況モニタリングの評価
    飯田真之, 志田有里, 番匠咲帆, 西岡達也, 松沼亮, 坂下明大, 木澤義之, 大村友博, 矢野育子
    第14回日本緩和医療薬学会年会, May 2021, Japanese
    Oral presentation

  • オピオイド鎮痛薬使用がん患者への薬剤師による外来電話サポートの介入効果
    志田有里, 飯田真之, 番匠咲帆, 蓼原瞬, 坂下明大, 久米学, 大村友博, 丹生健一, 木澤義之, 矢野育子
    第14回日本緩和医療薬学会年会, May 2021, Japanese
    Oral presentation

  • セルトラリンに起因するセロトニン症候群関連症状のリスク因子の探索
    山本和宏, 松山夏実, 國正淳一, 大村友博, 矢野育子
    日本薬学会第141年会, Mar. 2021, Japanese
    Poster presentation

  • 消化管上皮細胞モデルにおけるABCB1発現・機能に及ぼすエベロリムス長期曝露の影響
    中山優子, 高良恒史, 山本和宏, 大村友博, 矢野育子
    日本薬学会第141年会, Mar. 2021, Japanese
    Poster presentation

  • POLYMORPHISM OF CATECHOL-O-METHYLTRANSFERASE CHANGES PLASMA CONCENTRATION OF L-DOPA AND 3-O-METHYLDOPA
    Yamamoto J, Omura T, Kasamo S, Yamamoto S, Kawata M, Yonezawa A, Taruno Y, Endo H, Aizawa H, Sawamoto N, Matsubara K, Takahashi R, Tasaki Y
    15th International Conference on Alzheimer’s and Parkinson’s Diseases, Mar. 2021, English
    Poster presentation

  • Impact of sunitinib on the expression of cornifying factors in human epidermal 3D skin models
    Yoshida A, Yamamoto K, Ishida T, Omura T, Itoh T, Nishigori C, Sakane T, Yano I
    The Fourth International Cancer Research Symposium for Oncology Professionals,, Feb. 2021, English
    Oral presentation

  • 入退院支援業務における薬学的介入の現状−日本病院薬剤師会学術第５小委員会アンケート調査から−
    北田徳昭, 大村友博, 尾上雅英, 佐藤真由美, 柴田ゆうか, 堀内賢一, 宮崎俊明
    第42回日本病院薬剤師会近畿学術大会, Jan. 2021
    Poster presentation

  • 進行固形がん患者を対象とした心血管疾患予防のための降圧薬の使用実態に関する調査
    丹田雅明, 塩見真由, 山本和宏, 國正淳一, 槇本博雄, 大村友博, 矢野育子
    第42回日本病院薬剤師会近畿学術大会, Jan. 2021
    Poster presentation

  • 臨床検査値を活用した医薬品適正使用
    伊藤雄大, 山本和宏, 北村匠, 古川順也, 原田健一, 藤澤正人, 大村友博, 矢野育子
    第41回日本臨床薬理学会学術総会, Dec. 2020
    Poster presentation

  • 薬剤師による抗菌薬血中濃度測定オーダー登録と注射薬仮登録がもたらす実践的有用性の評価
    村川亜光, 山本和宏, 石井順子, 阪上倫行, 清水倫子, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020
    Poster presentation

  • 病棟薬剤師に対する手指衛生の教育効果と評価者としての薬学部実務実習生への波及効果
    柴田京香, 飯田真之, 宇田篤史, 八幡眞理子, 出田理恵, 大本暢子, 山本和宏, 大村友博, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020
    Oral presentation

  • レンバチニブによる有害事象の発生予測におけるALBI Gradeの有用性の検討
    松本由季, 榎本大智, 山本和宏, 大村友博, 小松昇平, 矢野嘉彦, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020
    Poster presentation

  • 工弁置換術後のワルファリン投与量設計におけるプロトロンビン時間国際標準比推移の現状と課題
    森岡朝美, 清水倫子, 山本和宏, 大村友博, 井上武, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020
    Poster presentation

  • パーキンソン病患者における非麦角系ドパミンアゴニストの認知機能への影響
    中村友紀, 重面雄紀, 今井哲司, 中川貴之, 樽野陽亮, 澤村正典, 大村友博, 松原和夫
    第30回日本医療薬学会年会, Oct. 2020
    Poster presentation

  • Slc52a3遺伝子欠損がマウス大脳皮質の形成に及ぼす影響
    金叢芸, 米澤淳, 吉松宏樹, 今井哲司, 小柳円花, 山西香里, 中川俊作, 糸原光太郎, 大村友博, 中川貴之, 永井純也, 松原和夫
    第15回トランスポーター研究会年会, Oct. 2020
    Oral presentation

  • ポリファーマシーに対する薬剤師介入の取り組み
    大村友博, 木村丈司, 山本和宏, 矢野育子
    日本病院薬剤師会 東北ブロック第10回学術大会, Jun. 2020, Japanese
    Nominated symposium

  • Physiologically-based pharmacokinetic modeling and simulation of serum risperidone and paliperidone concentrations in pregnant woman taking risperidone and in her baby
    Mahdy W, Yamamoto K, Ito T, Fujioka K, Horai T, Otsuka I, Imafuku H, Omura T, Iijima K, Yano I
    日本薬学会第140年会, Japanese
    Poster presentation

  • 腎移植後にスニチニブ治療を開始した腎癌患者におけるタクロリムス・エベロリムスの薬物動態モデル解析
    伊藤雄大, 山本和宏, 小川悟史, 古川順也, 原田健一, 藤澤正人, 大村友博, 矢野育子
    日本薬学会第140年会, Japanese
    Poster presentation

  • スニチニブによる表皮角化細胞のkeratin 6AおよびSERPINB1発現変動
    吉田彩夏, 山本和宏, 石田喬裕, 伊藤智雄, 大村友博, 矢野育子
    日本薬学会第140年会, Japanese
    Poster presentation

  • がん悪液質に対する補中益気湯の改善効果に関する調査
    北廣優実, 山本和宏, 大本暢子, 久米学, 芝野真喜雄, 大村友博, 矢野育子
    Japanese
    Poster presentation

  • Slc52a3遺伝子欠損がマウス大脳皮質の形成に及ぼす影響
    金叢芸, 米澤淳, 吉松宏樹, 今井哲司, 小柳円花, 山西香里, 中川俊作, 大村友博, 中川貴之, 永井純也, 松原和夫
    日本薬学会第140年会, Japanese
    Poster presentation

  • 乳児におけるテイコプラニン血中濃度の評価
    石井順子, 山本和宏, 阪上倫行, 西岡達也, 大村友博, 矢野育子
    第41回日本病院薬剤師会近畿学術大会, Feb. 2020, Japanese
    Poster presentation

  • 抗がん薬混合調製ロボットの導入と稼働状況
    伊藤恵, 丸上奈穂, 丹田雅明, 山口由加里, 野崎晃, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    第41回日本病院薬剤師会近畿学術大会, Feb. 2020, Japanese
    Poster presentation

  • Population pharmacokinetics of everolimus in renal transplant patients with multiple immunosuppressive therapy
    Sakaue T, Yamamoto K, Endo T, Ishimura T, Fujisawa M, Omura T, Yano I.
    日本薬物動態学会第34回年会, Dec. 2019, English
    Poster presentation

  • 新生児の先天性サイトメガロウイルス感染症患者におけるガンシクロビル血中濃度測定と生理学的薬物動態モデルを用いたシミュレーション
    山本和宏,大山正平,福嶋祥代,橋本真梨,山川恵,藤原尚子,藤岡一路,飯島一誠,大村友博,矢野育子
    第40回日本臨床薬理学会学術総会, Dec. 2019, Japanese
    Poster presentation

  • クロザピン及び代謝物の血中濃度における外来・入院の影響と体内動態解析
    小岸かれん, 大村友博, 山本将太, 中川俊作, 米澤淳, 糸原光太郎, 竹内理人, 松尾研志, 橋本凱朝, 諏訪太朗, 佐藤夕紀, 今井哲司, 中川貴之, 村井俊哉, 矢野育子, 松原和夫
    第29回日本医療薬学会年会, Nov. 2019, Japanese, Domestic conference
    Poster presentation

  • プロトコルおよび薬剤部門システムを活用したDOACの薬物相互作用マネジメント
    平山陽奈, 木村丈司, 高橋知子, 冨田猛, 野崎晃, 山本和宏, 大本暢子, 大村友博, 矢野育子
    第29回日本医療薬学会年会, Nov. 2019, Japanese, Domestic conference
    Oral presentation

  • プロトンポンプ阻害薬の院内フォームラリー策定による後発医薬品の使用促進と薬剤費の削減効果
    高橋知子, 木村丈司, 冨田猛, 野崎晃, 平山陽奈, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    第29回日本医療薬学会年会, Nov. 2019, Japanese, Domestic conference
    Oral presentation

  • ユビキチンリガーゼHRD1の安定化因子SEL1Lを標的とするmicroRNAの探索
    野村月渚, 大村友博, 今井哲司, 中川俊作, 米澤淳, 中川貴之, 佐藤夕紀, 松原和夫
    第69回日本薬学会関西支部総会・大会, Oct. 2019, Japanese, Domestic conference
    Oral presentation

  • GLP-1受容体作動薬リキシセナチドの抗パーキンソン病効果の検証
    内藤雅斗, 大村友博, 今井哲司, 佐藤夕紀, 中川俊作, 米澤淳, 中川貴之, 松原和夫
    第69回日本薬学会関西支部総会・大会, Oct. 2019, Japanese, Domestic conference
    Oral presentation

  • Oxicam-derived non-steroidal anti-inflammatory drugs protect against 1-methyl-4-phenyl pyridinium-induced cell death by suppressing of endoplasmic reticulum stress and mitochondrial dysfunction
    Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Tasaki Y, Yano I, Matsubara K
    Neuroscience 2019, Oct. 2019, English, International conference
    Poster presentation

  • Slc52a3 gene disruption affected the development of cerebral cortex in mice
    Jin C, Yonezawa A, Yoshimatsu H, Imai S, Koyanagi M, Yamanishi K, Nakagawa S, Omura T, Nakagawa T, Matsubara K
    Neuroscience 2019, Oct. 2019, English, International conference
    Poster presentation

  • THE AMOUNT OF DIETARY INTAKE AFFECTS WARFARIN SENSITIVITY INDEX AFTER CARDIOVASCULAR SURGERY
    Katada Y, Nakagawa S, Nishimura A, Sato Y, Taue H, Matsumura K, Yamamoto S, Yamazaki K, Minakata K, Yano I, Omura T, Imai S, Yonezawa A, Sato Y, Nakagawa T, Minatoya K, Matsubara K
    79th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2019, Sep. 2019, English, International conference

  • Impact of tacrolimus blood concentration on clinical outcomes in patients with Myasthenia Gravis
    Yamamoto S, Yonezawa A, Irachi Y, Hirozumi I, Katada Y, Nakagawa S, Sugimoto M, Yoshida Y, Omura T, Nakanishi E, Takahashi R, Matsubara K
    79th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2019, Sep. 2019, English, International conference

  • Add-on effects of tadalafil for tamsulosin-treated patients with benign prostatic hyperplasia suffering from residual lower urinary tract symptoms: a randomized, placebo-controlled, double-blind, crossover study
    Negoro H, Goto T, Akamatsu S, Terada N, Kobayashi T, Matsui T, Yamamoto T, Yonezawa A, Omura T, Matsubara K, Ogawa O
    49th International Continence Society (ICS) 2019, Sep. 2019, English, International conference
    Oral presentation

  • 遺伝子Slc52a3の欠損はマウス胎仔大脳皮質の発達に影響する。
    金叢芸, 米澤淳, 吉松宏樹, 今井哲司, 小柳円花, 山西香里, 中川俊作, 大村友博, 中川貴之, 松原和夫
    NEURO2019（第42回日本神経科学大会、第62回日本神経化学会大会）, Jul. 2019, Japanese, Domestic conference
    Oral presentation

  • パクリタキセル誘発末梢神経障害の発症におけるシュワン細胞依存的免疫反応の関与
    小柳円花, 今井哲司, 松本真有奈, 岩満優輝, 荻原孝史, 平岩怜, Ntogwa Mpumelelo, 佐藤夕紀, 中川俊作, 大村友博, 米澤淳, 中川貴之, 松原和夫
    NEURO2019（第42回日本神経科学大会、第62回日本神経化学会大会）, Jul. 2019, Japanese, Domestic conference
    Oral presentation

  • Improvement of Patient Care Quality through Pharmacist Intervention as A Member of Multidisciplinary Team Creates New Roles in Japan
    Matsubara K, Yonezawa A, Nakagawa T, Imai S, Omura T, Nakagawa S, Sato Y, Yano I
    Taiwan Society of Health-System Pharmacist (TSHP) Annual Conference, Nov. 2018, English, International conference
    [Invited]
    Invited oral presentation

  • 腎尿細管上皮線維芽細胞の相互作用におけるTMPRSS4の関与
    栗村万由子, 中川俊作, 佐藤夕紀, 大村友博, 今井哲司, 米澤淳, 中川貴之, 松原和夫
    第68回日本薬学会近畿支部総会・大会, Oct. 2018, Japanese, Domestic conference
    Oral presentation

  • 日本人リウマチ患者の服薬アドヒアランスが薬物治療の効果に及ぼす影響
    中川俊作, 中石真由美, 橋本 求, 伊藤宣, 山本 渉, 中嶋 蘭, 田中真生, 藤井隆夫, 佐藤夕紀, 大村友博, 今井哲司, 中川貴之, 米澤 淳, 今井博久, 三森経世, 松原和夫
    第12回次世代を担う若手医療薬科学シンポジウム, Sep. 2018, Japanese, Domestic conference
    Oral presentation

  • Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel: Phase I–IIa clinical trials in patients with limb or myocardial ischemia
    Nishio H, Masumoto H, Minakata K, Kumagai N, Yamamoto M, Omura T, Yokode M, Shimizu A, Matsubara K, Tabata Y, Minatoya K
    2018 TERMIS (Tissue Engineering & Regenerative Medicine International Society) World Congress, Sep. 2018, English, International conference
    Poster presentation

  • マクロファージに着目したHIV誘発末梢神経障害性疼痛の機序解明
    平岩 怜, 今井哲司, Mpumelelo Ntogwa, 小柳円花, 佐藤夕紀, 中川俊作, 大村友博, 米澤 淳, 中川貴之, 松原和夫
    第38回鎮痛薬・オピオイドペプチドシンポジウム, Aug. 2018, Japanese, Domestic conference
    Oral presentation

  • Disruption of Slc52a3 gene causes abnormalities of energy metabolism and brain development in mice with riboflavin deficiency
    Jin C, Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Nakagawa S, Imai S, Omura T, Nakagawa T, Matsubara K
    18th World Congress of Basic and Clinical Pharmacology (WCP2018), Jul. 2018, English, International conference
    Poster presentation

  • Role of ubiquitin ligase HRD1 in a cellular model of Parkinson’s disease
    Omura T, Matsuda H, Nomura L, Naito M, Nakagawa S, Imai S, Yonezawa A, Nakagawa T, Matsubara K
    18th World Congress of Basic and Clinical Pharmacology (WCP2018), Jul. 2018, English, International conference
    Poster presentation

  • 非ホジキンリンパ腫患者におけるリツキシマブの体内動態と臨床効果の相関
    大谷祐基, 米澤 淳, 森 万優子, 礒本 唯, 津田真弘, 池見泰明, 今井哲司, 中川俊作, 大村友博, 中川貴之, 北野俊行, 高折晃史, 松原和夫
    医療薬学フォーラム 2018／第26回クリニカルファーマシーシンポジウム, Jun. 2018, Japanese, Domestic conference
    Poster presentation

  • The usefulness of 21 autosomal short tandem repeat loci in paternity and sibling analysis
    Asari M, Okuda K, Tanaka H, Omura T, Isozaki S, Yamada H, Matsubara K, Shiono H, Shimizu K
    24th Congress of the International Academy of Legal Medicine (IALM), Jun. 2018, English, International conference
    Poster presentation

  • Paraquat cytotoxicity is prevented by 4-phenylbutyrate-induced phosphorylation of ERK2 in A549 cells
    Hoshina C, Okuda K, Tanaka H, Omura T, Horioka K, Asari M, Shiono H, Matsubara K, Shimizu K
    24th Congress of the International Academy of Legal Medicine (IALM), Jun. 2018, English, International conference
    Poster presentation

  • 血液内科外来における多剤処方減算対象症例に対する取り組み
    野口葉子, 尾崎淳子, 櫻井香織, 松村勝之, 吉田優子, 大村友博, 深津祥央, 米澤淳, 鎌苅裕道, 高折晃史, 松原和夫
    平成29年度大学病院情報マネジメント部門連絡会議, Jan. 2018, Japanese

  • 虚血性心疾患患者に対するbFGF含有ゼラチンハイドロゲルシート移植の安全性と有効性
    西尾博臣, 升本英利, 南方謙二, 熊谷基之, 山本雅哉, 大村友博, 横出正之, 清水章, 松原和夫, 田畑泰彦, 湊谷謙司
    第7回DDS再生医療研究会, Dec. 2017, Japanese

  • PK/PD analysis of rituximab in the patient with non-Hodgkin’s lymphoma
    Yonezawa A, Mori M, Otani Y, Isomoto Y, Tsuda M, Ikemi Y, Imai S, Omura T, Yano I, Kitano T, Takaori A, Matsubara K
    日本薬物動態学会第32回年会, Nov. 2017, Japanese

  • MPP+誘発神経細胞死に対するメロキシカムの神経保護作用とミトコンドリア障害及び小胞体ストレスの関与
    橋本凱朝, 大村友博, 笹岡美和, 大谷祐基, 中川俊作, 今井哲司, 米澤 淳, 中川貴之, 田﨑嘉一, 松原和夫
    第67回日本薬学会近畿支部総会・大会, Oct. 2017, Japanese

  • LC/TOF-MSを用いた抗体医薬品の体内動態解析
    大谷祐基, 米澤 淳, 津田真弘, 今井哲司, 池見泰明, 大村友博, 中川俊作, 中川貴之, 矢野育子, 松原和夫
    第42回日本医用マススペクトル学会年会, Sep. 2017, Japanese

  • 塩基性線維芽細胞増殖因子含有ゼラチンハイドロゲルシートによる心筋再生治療の2治験例
    升本英利, 南方謙二, 西尾博臣, 山本雅哉, 大村友博, 横出正之, 清水 章, 松原和夫, 田畑泰彦, 坂田隆造, 湊谷謙司
    第33回日本DDS学会学術大会, Jul. 2017, Japanese

  • 薬毒物による間質性腎炎の発症における腸内細菌叢の関与
    高尾翔太, 中川俊作, 栗村万由子, 中村美沙子, 大谷祐基, 大村友博, 今井哲司, 米澤 淳, 中川貴之, 松原和夫
    医療薬学フォーラム2017/第25回クリニカルファーマシーシンポジウム, Jul. 2017, Japanese

  • 4-フェニル酪酸と抗酸化剤のパラコート毒性に対する細胞保護メカニズムの比較
    大村友博, 保科千里, 奥田勝博, 田中宏樹, 磯崎翔太郎, 早川輝, 浅利優, 塩野寛, 松原和夫, 清水惠子
    第101次日本法医学会学術全国集会, Jun. 2017, Japanese

  • 高湿度条件における口腔内細胞のDNA分解
    松浦宏晃, 浅利優, 保科千里, 奥田勝博, 田中宏樹, 北村麻奈, 大村友博, 松原和夫, 塩野寛, 清水惠子
    第101次日本法医学会学術全国集会, Jun. 2017, Japanese

  • 微小管阻害薬によるシュワン細胞の脱分化を伴った脱髄が抗がん剤誘発末梢神経障害の発症に関与する
    松本真有奈, 今井哲司, 小柳円花, 中里唯, Ziauddin Azimi, 米澤 淳, 大村友博, 中川俊作, 金子周司, 中川貴之, 松原和夫
    第90回日本薬理学会年会, Mar. 2017, Japanese

  • ロフラゼプを周産期に使用した褥婦の母乳と新生児血中濃度の2症例
    森田真樹子, 米澤淳, 大村友博, 南いく子, 中川俊作, 杉本充弘, 都築徹教, 今井哲司, 松原和夫
    第38回日本病院薬剤師会近畿学術大会, Feb. 2017, Japanese

  • 重症筋無力症の臨床アウトカムとタクロリムス血中濃度の関連性
    伊良知由梨, 山本将太, 米澤 淳, 廣住育美, 杉本充弘, 吉田優子, 中川俊作, 大村友博, 松原和夫
    第38回日本病院薬剤師会近畿学術大会, Feb. 2017, Japanese

  • 心臓血管外科領域におけるbFGF徐放化ゼラチンハイドロゲルの臨床試験の検討
    升本英利, 南方謙二, 熊谷基之, 西尾博臣, 山本雅哉, 大村友博, 横出正之, 清水 章, 松原和夫, 田畑泰彦, 坂田隆造, 湊谷謙司
    第6回DDS再生医療研究会, Dec. 2016, Japanese

  • 白金製剤オキサリプラチンによる末梢神経障害時の血流障害を介したTRPA1過敏化機構
    鄭 有奈, 宗 可奈子, 三宅崇仁, 中川俊作, 大村友博, 米澤 淳, 今井哲司, 中川貴之, 金子周司, 松原和夫
    第130回日本薬理学会近畿部会, Nov. 2016, Japanese

  • 社会的挫折ストレス負荷によるうつ病モデルマウスにおけるベンゾジアゼピン系睡眠薬による睡眠作用の効力変化
    辻 光貴, 今井哲司, 宮山 大, 清水佑美, 重面雄紀, 西谷直哉, 米澤 淳, 大村友博, 中川俊作, 金子周司, 中川貴之, 松原和夫
    第130回日本薬理学会近畿部会, Nov. 2016, Japanese

  • Different toxicological mechanisms of cisplatin and oxaliplatin in renal epithelial cell lines
    Zhang Y, Yonezawa A, Nakagawa S, Nimura A, Yoshimatsu H, Omura T, Imai S, Nakagawa T, Matsubara K
    第10回次世代を担う若手医療薬科学シンポジウム, Nov. 2016, Japanese

  • 腎臓病モデルラットにおけるリツキシマブの薬物動態評価
    岡田凌太, 大谷祐基, 米澤 淳, 今井哲司, 磯本 唯, 池見泰明, 津田真弘, 中川俊作, 大村友博, 中川貴之, 北野俊行, 高折晃史, 松原和夫
    第66回日本薬学会近畿支部総会・大会, Oct. 2016, Japanese

  • 貧血時におけるタクロリムスの体内動態
    赤田菜々, 中川俊作, 大村友博, 今井哲司, 米澤 淳, 中川貴之, 矢野育子, 松原和夫
    第66回日本薬学会近畿支部総会・大会, Oct. 2016, Japanese

  • Different pharmacological characteristics of cisplatin and oxaliplatin in renal epithelial cell lines
    Zhang Y, Yonezawa A, Nakagawa S, Nimura A, Yoshimatsu H, Omura T, Imai S, Nakagawa T, Matsubara K
    第26回日本医療薬学会年会, Sep. 2016, Japanese

  • Assessment of structural alterations of Rituximab in vivo and correlation with ADCC and CDC activities
    Otani Y, Yonezawa A, Imai S, Tsuda M, Ikemi Y, Omura T, Nakagawa S, T Nakagawa T, Matsubara K
    第26回日本医療薬学会年会, Sep. 2016, Japanese

  • Differential effects of paclitaxel and platinum derivatives on primary cultured Schwann cells participate in the chemotherapy-induced peripheral neuropathy pathogenesis
    Koyanagi M, Imai S, Nakazato Y, Matsumoto M, Yonezawa A, Nakagawa S, Omura T, Nakagawa T, Matsubara K
    第26回日本医療薬学会年会, Sep. 2016, Japanese

  • 社会的挫折ストレス負荷によるうつ病モデルマウスにおけるブロチゾラム誘発睡眠作用の効力変化に関する行動薬理学的研究
    宮山 大, 今井哲司, 辻 光貴, 重面雄紀, 米澤 淳, 大村友博, 中川俊作, 矢野育子, 中川貴之, 松原和夫
    第24回クリニカルファーマシーシンポジウム/医療薬学フォーラム2016, Jun. 2016

  • 短時間の増幅反応によるミトコンドリアDNA 多型解析
    浅利優, 奥田勝博, 大村友博, 塩野寛, 松原和夫, 清水惠子
    第100次日本法医学会学術全国集会, Jun. 2016, Japanese

  • デートレイプドラッグは被害者の危機回避行動を鈍くする
    松原和夫, 大村友博, 奥田勝博, 浅利優, 田中宏樹, 粟屋敏雄, 磯崎翔太郎, 山田ひろみ, 塩野寛, 清水惠子
    第100次日本法医学会学術全国集会, Jun. 2016, Japanese

  • シュワン細胞に着目したタキサン系あるいは白金系抗がん剤誘発末梢神経障害の発症機序の相違
    中里唯, 今井哲司, 小柳円花, Ziauddin Azimi, 米澤 淳, 大村友博, 中川俊作, 金子周司, 中川貴之, 松原和夫
    第89回日本薬理学会年会, Mar. 2016, Japanese

  • インフリキシマブ先行品と後続品における糖鎖構造の比較
    津田真弘, 津田真弘, 大谷祐基, 米澤淳, 池見泰明, 大村友博, 中川俊作, 今井哲司, 中川貴之, 矢野育子, 矢野育子, 松原和夫
    日本薬学会年会要旨集(CD-ROM), Mar. 2016, Japanese

  • 社会的敗北ストレス誘発うつ病モデルにおけるブロチゾラム誘発睡眠作用の効力変化
    辻光貴, 今井哲司, 宮山大, 西谷直也, 米澤淳, 大村友博, 中川俊作, 中川貴之, 金子周司, 松原和夫
    日本薬学会年会要旨集(CD-ROM), Mar. 2016, Japanese

  • Assessment of structural alterations of Rituximab in rat
    Otani Y, Yonezawa A, Imai S, Tsuda M, Ikemi Y, Omura T, Nakagawa S, Nakagawa T, Matsubara K
    The 4th International Symposium of Training Plan for Oncology Professional, Feb. 2016, English, International conference
    Oral presentation

  • 虚血性心筋症に対する新たなオプションとしての血管新生療法の可能性
    熊谷基之, 南方謙二, 山本雅哉, 大村友博, 米澤淳, 坂本和久, 西尾博臣, 中田朋宏, 上原京勲, 阪口仁寿, 山崎和裕, 池田義, 松原和夫, 田畑泰彦, 坂田隆造
    日本バイオマテリアル学会大会予稿集, Nov. 2015, Japanese

  • 高速PCRに基づいたミトコンドリアDNA多型解析
    浅利優, 奥田勝博, 大村友博, 塩野寛, 松原和夫, 清水惠子
    日本法科学技術学会誌, Oct. 2015, Japanese

  • 医師と薬剤師が協働する乳癌術後ホルモン療法教室による患者の理解度の変化
    猪熊容子, 山本浩貴, 池見泰明, 石塚良子, 深津祥央, 大村友博, 中川俊作, 今井哲司, 鈴木栄治, 竹内恵, 戸井雅和, 松原和夫
    日本医療薬学会年会講演要旨集, Oct. 2015, Japanese

  • 悪性黒色腫に対するニボルマブ治療における免疫関連有害反応の検討
    山本将太, 長谷川真理, 吉良俊彦, 池見泰明, 大村友博, 矢野育子, 藤澤章弘, 椛島健治, 松原和夫
    日本医療薬学会年会講演要旨集, Oct. 2015, Japanese

  • EFFECT OF ITRACONAZOLE ON PHARMACOKINETICS OF TACROLIMUS AND CYCLOSPORINE IN PATIENTS WITH LUNG TRANSPLANTATION
    Matsuda, Y, Yano, I, Imai, S, Yonezawa, A, Yamamoto, T, Sugimoto, M, Tsuda, M, Tsuzuki, T, Nakagawa, S, Omura, T, Nakagawa, T, Chen, F, Date, H, Matsubara, K
    75th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2015, Sep. 2015, English, International conference
    Oral presentation

  • CHRONIC KIDNEY DISEASE AFTER PLATINUM BASED CHEMOTHERAPY
    Nakagawa, S, Shinke, H, Okuda, Y, Nakamura, M, Omura, T, Imai, S, Yonezawa, A, Yano, I, Nakagawa, T, Matsubara, K
    75th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2015, Sep. 2015, English, International conference
    Oral presentation

  • The Contribution of GMP-grade Hospital Preparation to Translational Research.
    Yonezawa A, Kajiwara M, Minami I, Omura T, Nakagawa S, Matsubara K
    YAKUGAKU ZASSHI, Aug. 2015, Japanese,   Translational research is important for applying the outcomes of basic research studies to practical medical treatments. In exploratory early-phase clinical trials for an innovative therapy, researchers should generally manufacture investigational agents by themselves. To provide investigational agents with safety and high quality in clinical studies, appropriate production management and quality control are essential. In the Department of Pharmacy of Kyoto University Hospital, a manufacturing facility for sterile drugs was established, independent of existing manufacturing facilities. Manuals on production management and quality control were developed according to Good Manufacturing Practices (GMP) for Investigational New Drugs (INDs). Advanced clinical research has been carried out using investigational agents manufactured in our facility. These achievements contribute to both the safety of patients and the reliability of clinical studies. In addition, we are able to do licensing-out of our technique for the manufacture of investigational drugs. In this symposium, we will introduce our GMP grade manufacturing facility for sterile drugs and discuss the role of GMP grade hospital preparation in translational research.
    [Invited]
    Oral presentation

  • 薬力学的特徴に基づくシスプラチンの腎毒性発現機序の解明
    張いん鵬, 米澤淳, 中川俊作, 二村明憲, 吉松宏樹, 大村友博, 今井哲司, 中川貴之, 松原和夫
    医療薬学フォーラム講演要旨集, Jun. 2015, Japanese

  • 4種類のユニバーサル配列を用いた21座位STR解析法の開発
    浅利優, 奥田勝博, 保科千里, 大村友博, 塩野寛, 松原和夫, 清水惠子
    日本法医学雑誌, May 2015, Japanese

  • リツキシマブの生体内における構造変化の評価
    大谷祐基, 米澤淳, 今井哲司, 津田真弘, 池見泰明, 大村友博, 中川俊作, 中川貴之, 松原和夫
    日本薬剤学会年会講演要旨集(Web), 2015, Japanese

  • EGFR阻害薬による肺障害とeIF2αのリン酸化
    小山智志, 大村友博, 中川俊作, 今井哲司, 米澤淳, 中川貴之, 松原和夫
    日本薬学会年会要旨集(CD-ROM), 2015, Japanese

  • アファチニブ投与患者における多職種が連携した患者教育体制の確立とその効果
    池見泰明, 寺尾真琴, 礒本唯, 大村友博, 深津祥央, 浜辺陽子, 中島瞳, 永井宏樹, 永井宏樹, 金永学, 武藤学, 松原和夫
    日本癌治療学会学術集会(Web), 2015, Japanese

  • 生体内におけるリツキシマブの経時的構造変化の解析
    大谷祐基, 米澤淳, 今井哲司, 津田真弘, 兼吉真千子, 池見泰明, 大村友博, 中川俊作, 矢野育子, 北野俊行, 高折晃史, 松原和夫
    日本癌治療学会学術集会(Web), 2015, Japanese

  • 年齢推定における残存歯数・咬耗度の有用性について
    岡久美子, 吉田将亜, 松田光悦, 浅利優, 磯崎翔太郎, 市丸千聖, 間瀬田千香暁, 塩野寛, 清水惠子, 大村友博, 松原和夫, 矢島大介
    法医学の実際と研究, Nov. 2014, Japanese

  • LC/TOF‐MSを用いた抗体医薬品の糖鎖解析
    大谷祐基, 松村健吾, 米澤淳, 大村友博, 津田真弘, 中川貴之, 松原和夫
    日本医療薬学会年会講演要旨集, Aug. 2014, Japanese

  • LC/TOF‐MSによるG‐CSFバイオ後続品の定性分析
    松村健吾, 大谷祐基, 大村友博, 米澤淳, 津田真弘, 吉貴達寛, 松原和夫
    日本医療薬学会年会講演要旨集, Aug. 2014, Japanese

  • トレーシングレポート(服薬情報提供書)を利用した病診薬連携の推進
    礒本唯, 萱野勇一郎, 池見泰明, 杉本充弘, 大村友博, 米澤淳, 深津祥央, 松原和夫
    日本医療薬学会年会講演要旨集, Aug. 2014, Japanese

  • クロザピンによる副作用の実態調査と薬剤師による介入の効果
    八田眞菜美, 重面雄紀, 山本将太, 萱野勇一郎, 大村友博, 矢野育子, 諏訪太朗, 村井俊哉, 松原和夫
    日本医療薬学会年会講演要旨集, Aug. 2014, Japanese

  • リボフラビントランスポータRFVT変異による希少疾患BVVLSの発症
    米澤淳, 八尾祉顕, 吉松宏樹, 菅野久美子, 山西香里, 大村友博, 中川俊作, 松原和夫
    医療薬学フォーラム講演要旨集, Jun. 2014, Japanese, Domestic conference
    Nominated symposium

  • Sodium tauroursodeoxycholate and 4-phenyl butyrate, chemical chaperones, prevent paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells
    Omura, T, Asari, M, Hoshina, C, Koyama, S, Maseda, C, Nakagawa, S, Shiono, H, Shimizu, K, Matsubara, K
    9th International Symposium ADVANCES IN LEGAL MEDICINE, Jun. 2014, English, International conference
    Oral presentation

  • Genotyping of 38 Insertion/deletion polymorphisms for human identification using universal fluorescent PCR
    Oka, K, Asari, M, Omura, T, Isozaki, S, Yoshida, N, Maseda, C, Yajima, D, Matsubara, K, Shiono, H, Matsuda, M, Shimizu, K
    9th International Symposium ADVANCES IN LEGAL MEDICINE, Jun. 2014, English, International conference
    Oral presentation

  • Fast PCR-based genotyping of 25 autosomal short tandem repeats and amelogenin using fluorescent universal primers
    Asari, M, Oka, K, Hoshina, C, Isozaki, S, Okuda, K, Yajima, D, Maseda, C, Omura, T, Matsubara, K, Shiono, H, Shimizu, K
    9th International Symposium ADVANCES IN LEGAL MEDICINE, Jun. 2014, English, International conference
    Oral presentation

  • Immunohistochemical examinations of CIRP and RBM3 are useful for diagnosing the cse of death under hypothermal conditions
    Ohtani, S, Shimizu, K, Asari, M, Maseda, C, Yajima, D, Okuda, K, Oka, K, Doi, H, Yamada, H, Hoshina, C, Isozaki, S, Kitamura, A, Yoshida, A, Nakamura, A, Suzuki, A, Shiono, H, Omura, T, Matsubara, K
    9th International Symposium ADVANCES IN LEGAL MEDICINE, Jun. 2014, English, International conference
    Oral presentation

  • 院内製剤のトレーサビリティの向上を目指した品質管理システムの構築
    山本崇, 南いく子, 志田あゆみ, 大澤理代, 山際岳朗, 大村友博, 米澤淳, 深津祥央, 矢野育子, 松原和夫
    医療薬学フォーラム講演要旨集, Jun. 2014, Japanese

  • イヌサフラン誤食による中毒死例
    間瀬田千香暁, 奥田勝博, 矢島大介, 磯崎翔太郎, 岡久美子, 大村友博, 浅利優, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, May 2014, Japanese

  • 治験薬GMP基準の院内製剤製造によるトランスレーショナルリサーチへの貢献
    米澤淳, 梶原望渡, 南いく子, 大村友博, 中川俊作, 松原和夫
    日本薬学会年会要旨集(CD-ROM), Mar. 2014, Japanese, Domestic conference
    Nominated symposium

  • RFVT3ノックアウトマウスにおけるリボフラビン恒常性の破綻
    吉松宏樹, 米澤淳, 山西香里, 八尾祉顕, 中川俊作, 大村友博, 松原和夫
    日本薬学会年会要旨集(CD-ROM), 2014, Japanese

  • 多座位挿入欠失多型解析に基づく個人識別法の開発
    岡久美子, 浅利優, 大谷静治, 土井大輝, 山田ひろみ, 保科千里, 松田都久美, 北村麻奈, 吉田あやか, 間瀬田千香暁, 塩野寛, 清水惠子, 大村友博, 松原和夫, 吉田将亜, 毎熊浩二, 松田光悦
    法医学の実際と研究, Nov. 2013, Japanese

  • 北海道沿岸における珪藻分布の解析報告~第三報~
    毎熊浩二, 浅利優, 山田ひろみ, 松田都久美, 岡久美子, 北村麻奈, 吉田あやか, 土井大輝, 保科千里, 大谷静治, 間瀬田千香暁, 塩野寛, 清水惠子, 大村友博, 早川輝, 村上学, 的場光太郎, 寺沢浩一, 山田直弥, 中村一, 阿部祐亮, 三和正人, 吉田幸夫
    法医学の実際と研究, Nov. 2013, Japanese

  • Mammalian target of rapamycin (mTOR) mediates neuroprotection by oxicam non-steroidal anti-inflammatory drugs against MPP+-induced SH-SY5Y cell death
    Tasaki, Y, Ono, T, Yamamoto, J, Ohkubo, T, Noda, T, Omura, T, Suno, M, Matsubara, K
    Neuroscience 2013, Nov. 2013, English, International conference
    Oral presentation

  • パラコート誘発細胞死におけるユビキチンリガーゼHRD1,Parkinの役割とケミカルシャペロンによる細胞死抑制効果の検討
    大村友博, 山本譲, 浅利優, 岡久美子, 保科千里, 米澤淳, 増田智先, 粟屋敏雄, 田崎嘉一, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    中毒研究, Sep. 2013, Japanese

  • 大量服薬によるフェノバルビタール中毒症状を呈した1例
    八田眞菜美, 西岡由貴, 大村友博, 増田智先, 矢野育子, 松原和夫
    中毒研究, Sep. 2013, Japanese

  • 薬物性腎障害とトランスポータ機能との関連
    増田智先, 米澤 淳, 大村友博, 松原和夫
    第29回日本DDS学会学術集会, Jul. 2013, Japanese, Domestic conference
    [Invited]
    Nominated symposium

  • EGFR阻害薬の毒性発現と小胞体ストレスの関与
    小山智志, 大村友博, 笹岡美和, 米澤淳, 福土将秀, 増田智先, 松原和夫
    医療薬学フォーラム講演要旨集, Jul. 2013, Japanese

  • パラコート毒性における小胞体ストレスの関与とケミカルシャペロンによる細胞死抑制効果
    大村友博, 浅利優, 岡久美子, 保科千里, 米澤淳, 増田智先, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    日本法医学雑誌, May 2013, Japanese

  • LC‐MS/MSによるチオ硫酸塩の分析(第2報)
    間瀬田千香暁, 浅利優, 岡久美子, 山田ひろみ, 大村友博, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, May 2013, Japanese

  • Real‐time PCRを用いたCYP3A5及びCYP2C19の遺伝子多型迅速判定法の開発と生体肝移植におけるタクロリムスTDM業務への応用
    山本譲, 大村友博, 田崎嘉一, 浅利優, 岡久美子, 米澤淳, 増田智先, 粟屋敏雄, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    日本薬学会年会要旨集(CD-ROM), 2013, Japanese

  • Myeloid cell leukemia‐1(Mcl‐1)はSH‐SY5Y細胞のMPP+誘発アポトーシスに対して保護作用を持つ
    田崎嘉一, 吉田光一, 小野尚志, 山本譲, 坂口智己, 飯田慎也, 大滝康一, 神山直也, 木村周古, 大久保知子, 野田敏宏, 大村友博, 粟屋敏雄, 松原和夫
    日本薬学会年会要旨集(CD-ROM), 2013, Japanese

  • 抗てんかん薬クロバザムの臨床効果に対するCYP2C19遺伝子多型の重要性
    端幸代, 柴田茉衣, 増田智先, 大村友博, 松原和夫, 木下真幸子, 松本理器, 池田昭夫, 高橋良輔, 矢野育子
    日本薬学会年会要旨集(CD-ROM), 2013, Japanese

  • 頭蓋骨からの帰属集団判定;Fordisc 3.0の法医実務への応用
    岡久美子, 浅利優, 大村友博, 間瀬田千香暁, 塩野寛, 清水惠子, 吉田将亜, 松田光悦, 坂上和弘, 松原和夫, 毎熊浩二
    法医学の実際と研究, Nov. 2012, Japanese

  • 調理用液化ブタン吸入による死亡事例
    間瀬田千香暁, 岡久美子, 大村友博, 浅利優, 毎熊浩二, 大谷静治, 塩野寛, 清水恵子, 松原和夫
    法医学の実際と研究, Nov. 2012, Japanese

  • プランクトン検査における壊機法の改良と北海道内のプランクトン分布
    山田ひろみ, 松田都久美, 土井大輝, 間瀬田千香暁, 吉田あやか, 岡久美子, 浅利優, 大村友博, 大谷静治, 塩野寛, 清水惠子, 松原和夫, 毎熊浩二
    法医学の実際と研究, Nov. 2012, Japanese

  • Oxicam non-steroidal anti-inflammatory drugs ameliorate motor dysfunction and dopaminergic degeneration by maintaining Akt-signaling in a mouse Parkinson’s disease model
    Tasaki, Y, Yamamoto, J, Ohkubo, T, Noda, T, Omura, T, Ono, T, Kimura, N, Suno, M, Sakaguchi, T, Matsubara, K
    Neuroscience 2012, Oct. 2012, English, International conference
    Oral presentation

  • 病棟常駐薬剤師によるTDMオーダ入力は対象薬剤の適正使用を推進する―医政局長通知「医療スタッフの協働・連携によるチーム医療の推進について」のTDM部門における具体化―
    山本譲, 大村友博, 粟屋敏雄, 田原克寿, 山下恭範, 小枝正吉, 飯田慎也, 木村周古, 山本香緒里, 大滝康一, 原千恵子, 山田峻史, 都築仁美, 神山直也, 山本久仁子, 田崎嘉一, 松原和夫
    TDM研究, May 2012, Japanese

  • 人工核酸LNAを導入した蛍光ユニバーサルプライマーを用いたSTR解析法の開発
    浅利優, 大村友博, 岡久美子, 間瀬田千香暁, 塩野寛, 松原和夫, 松田光悦, 清水恵子
    日本法医学雑誌, May 2012, Japanese

  • パラコート毒性における小胞体ストレス応答分子の関与とケミカルシャペロンによる細胞保護効果の検討
    大村友博, 浅利優, 岡久美子, 保科千里, 粟屋敏雄, 田崎嘉一, 間瀬田千香暁, 塩野寛, 松原和夫, 清水惠子
    日本法医学雑誌, May 2012, Japanese

  • 低温環境下での死亡における低温ショック蛋白CIRPの発現
    大谷静治, 間瀬田千香暁, 浅利優, 岡久美子, 大村友博, 松田都久美, 北村麻奈, 松原和夫, 塩野寛, 清水恵子
    日本法医学雑誌, May 2012, Japanese

  • オキシカム系NSAIDsは,MPTP反復投与パーキンソン病モデルにおいて黒質線条体神経を保護し,行動異常を改善する
    田崎嘉一, 山本譲, 坂口智己, 野田敏宏, 大村友博, 神山直也, 吉田光一, 大久保知子, 松原和夫
    日本薬学会年会要旨集, Mar. 2012, Japanese

  • パラコート毒性における小胞体ストレス応答分子の関与とケミカルシャペロンによる細胞保護効果の検討
    大村友博, 浅利優, 山本譲, 神山直也, 岡久美子, 保科千里, 粟屋敏雄, 田崎嘉一, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫
    日本薬学会年会要旨集, Mar. 2012, Japanese

  • Structural specificity of Akt-mediated neuroprotection by oxicam non-steroidal anti-inflammatory drugs against 1-methyl-4-phenyl pyridinium-induced cell death
    Tasaki, Y, Yamamoto, J, Omura, T, Noda, T, Kamiyama, N, Yoshida, K, Satomi, M, Sakaguchi, T, Asari, M, Ohkubo, T, Shimizu, K, Matsubara, K
    WFN World Congress on Parkinson’s Disease and Related Disorders 2011, Dec. 2011, English, International conference
    Oral presentation

  • LC/MS/MSによる術中突然死体の組織中リドカイン濃度の測定
    間瀬田千香暁, 大村友博, 浅利優, 岡久美子, 大谷静治, 塩野寛, 清水惠子, 松原和夫
    法医学の実際と研究, Nov. 2011, Japanese

  • 剖検例における尿中ケトン体の試験紙法による比較検討
    山田ひろみ, 間瀬田千香暁, 浅利優, 岡久美子, 吉田あやか, 大谷静治, 塩野寛, 清水惠子, 大村友博, 松原和夫
    法医学の実際と研究, Nov. 2011, Japanese

  • 積雪寒冷地での凍死診断における左右心臓血酸素化ヘモグロビン含有量の差
    清水惠子, 浅利優, 大村友博, 山田ひろみ, 松田都久美, 北村麻奈, 吉田あやか, 大谷静治, 間瀬田千香暁, 塩野寛, 松原和夫
    法医学の実際と研究, Nov. 2011, Japanese

  • Identifiler Kitを用いた身元確認のためのDNA鑑定における問題点について
    浅利優, 岡久美子, 大村友博, 大谷静治, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫, 松田光悦
    法医学の実際と研究, Nov. 2011, Japanese

  • パラコート中毒による肺毒性におけるセロトニン受容体の関与
    大村友博, 浅利優, 保科千里, 間瀬田千香暁, 塩野寛, 清水惠子, 田崎嘉一, 松原和夫
    法医学の実際と研究, Nov. 2011, Japanese

  • 抗ヒトケラチン抗体を用いた浴槽内溺水診断の検討
    大谷静治, 浅利優, 大村友博, 間瀬田千香暁, 山田ひろみ, 松田都久美, 北村麻奈, 吉田あやか, 岡久美子, 保科千里, 土井大輝, 塩野寛, 清水恵子, 松原和夫
    法医学の実際と研究, Nov. 2011, Japanese

  • 下顎切歯咬耗度からの年齢推定方法についての検討
    岡久美子, 浅利優, 大谷静治, 山田ひろみ, 土井大輝, 保科千里, 松田都久美, 北村麻奈, 吉田あやか, 間瀬田千香暁, 塩野寛, 清水惠子, 大村友博, 松原和夫, 吉田将亜, 松田光悦
    法医学の実際と研究, Nov. 2011, Japanese

  • Zonisamide increases human HRD1 protein resulting in the repression of caspase-3 activation and cell death caused by the ER stress in SH-SY5Y cells
    Omura, T, Asari, M, Tasaki, Y, Hoshina, C, Yamamoto, J, Kamiyama, N, Oka, K, Matsuda, T, Kitamura, A, Maseda, C, Shimizu, K, Matsubara, K
    Neuroscience 2011, Nov. 2011, English, International conference
    Oral presentation

  • TDMオーダリングシステムおよび臨床検査情報システムを統合したハイブリッドTDMシステムの構築
    山本譲, 大村友博, 神山直也, 山田峻史, 田原克寿, 都築仁美, 粟屋敏雄, 大滝康一, 田崎嘉一, 松原和夫
    医療薬学フォーラム講演要旨集, Jul. 2011, Japanese

  • LC/MS/MSを用いた小児肺動脈性肺高血圧患者血中ボセンタンTDM
    神山直也, 田崎嘉一, 大村友博, 小城香緒里, 田原克寿, 山本譲, 太田圭, 杉本昌也, 梶濱あや, 梶野浩樹, 松原和夫
    医療薬学フォーラム講演要旨集, Jul. 2011, Japanese

  • パラコート曝露による肺毒性とセロトニン受容体の関与
    大村友博, 浅利優, 保科千里, 間瀬田千香暁, 田崎嘉一, 塩野寛, 松原和夫, 清水惠子
    中毒研究, Jun. 2011, Japanese

  • パーキンソン病薬物治療におけるL‐dopaおよびその代謝物の血中濃度モニタリング―エンタカポン併用療法における遺伝子多型情報応用の検討―
    山本譲, 田崎嘉一, 大村友博, 吉田光一, 飯田慎也, 神山直也, 遠藤寿子, 浅野目明日香, 斎藤司, 澤田潤, 片山隆行, 長谷部直幸, 松原和夫
    TDM研究, Jun. 2011, Japanese

  • アリル特異的伸長反応による微量DNAからのABO式血液型判定
    浅利優, 岡久美子, 大村友博, 間瀬田千香暁, 塩野寛, 清水惠子, 松原和夫, 松田光悦
    DNA多型, May 2011, Japanese

  • 液体クロマトグラフタンデム質量分析計(LC‐MS/MS)によるチオ硫酸塩の分析
    間瀬田千香暁, 岡久美子, 松田都久美, 北村麻奈, 吉田あやか, 大村友博, 浅利優, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, May 2011, Japanese

  • 21座位STR判定に基づく身元確認のためのDNA鑑定
    浅利優, 大村友博, 岡久美子, 山田ひろみ, 土井大輝, 間瀬田千香暁, 塩野寛, 松原和夫, 松田光悦, 清水惠子
    日本法医学雑誌, May 2011, Japanese

  • パラコート誘発肺毒性における小胞体ストレス応答遺伝子の関与
    大村友博, 浅利優, 保科千里, 岡久美子, 間瀬田千香暁, 田崎嘉一, 塩野寛, 松原和夫, 清水惠子
    日本法医学雑誌, May 2011, Japanese

  • オキシカム系NSAIDsによる神経細胞死抑制作用はAkt/mTOR経路を介する
    田崎嘉一, 山本譲, 大久保知子, 須野学, 大村友博, 神山直也, 吉田光一, 野田敏宏, 坂口智己, 松原和夫
    日本薬学会年会要旨集, Mar. 2011, Japanese

  • パラコート誘発肺毒性における小胞体ストレス関連分子の関与
    大村友博, 浅利優, 保科千里, 間瀬田千香暁, 田崎嘉一, 塩野寛, 清水惠子, 松原和夫
    日本薬学会年会要旨集, Mar. 2011, Japanese

  • エンタカポン併用療法におけるL‐dopa血中濃度とCOMT遺伝子多型の関連性に関する検討
    山本譲, 田崎嘉一, 飯田慎也, 大村友博, 神山直也, 吉田光一, 遠藤寿子, 浅野目明日香, 斎藤司, 澤田潤, 片山隆行, 長谷部直幸, 松原和夫
    日本薬学会年会要旨集, Mar. 2011, Japanese

  • 二段階PCRを用いた簡便なABO式血液型判定法の開発
    浅利優, 間瀬田千香暁, 塩野寛, 清水惠子, 大村友博, 松原和夫
    法医学の実際と研究, Nov. 2010, Japanese

  • 新薬学教育6年制における実務実習モデル・コアカリキュラム「中毒医療への貢献」への対応―法医学講座と連携した救急医療における濫用薬物スクリーニングと血中アルコール濃度測定
    大村友博, 麻下智加, 田崎嘉一, 飯田慎也, 山本譲, 須野学, 粟屋敏雄, 三好敏之, 松原和夫, 間瀬田千香暁, 浅利優, 清水惠子
    法医学の実際と研究, Nov. 2010, Japanese

  • LDR‐PCR法を用いた一塩基多型検出によるABO式血液型検査
    浅利優, 大村友博, 間瀬田千香暁, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, May 2010, Japanese

  • 抗ヒトケラチン抗体を用いた浴槽内溺水診断の検討
    大谷静治, 浅利優, 大村友博, 間瀬田千香暁, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, May 2010, Japanese

  • オキシカム系NSAIDsによるCOX非依存的神経細胞死抑制作用の構造特異性
    田崎嘉一, 野田敏宏, 大久保知子, 山本譲, 大村友博, 飯田慎也, 坂口智己, 松原和夫
    日本薬学会年会要旨集, Mar. 2010, Japanese

  • Human HRD1 involved in the degradation of unfolded proteins has other functions than ubiquitin ligase activity in its transmembrane and proline-rich domains
    Omura, T, Kaneko, M, Okuma, Y, Nomura, Y
    Neuroscience 2009, Oct. 2009, English, International conference
    Oral presentation

  • Meloxicam protects against 1-methyl-4-phenyl pyridinium-induced cell death via phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells
    Tasaki, Y, Okubo, T, Yamada, T, Omura, T, Suno, M, Iida, S, Satomi, M, Sakaguchi, T, Asari, M, Shimizu, K, Matsubara, K
    Neuroscience 2009, Oct. 2009, English, International conference
    Oral presentation

  • 15座位のSTR解析により低い尤度比を示した身元確認のためのDNA鑑定事例
    浅利優, 大村友博, 間瀬田千香暁, 松原和夫, 塩野寛, 清水惠子
    日本法医学雑誌, Apr. 2009, Japanese

  • 大腿骨頭窩の形態を用いた年齢推定法の法医実務における有用性
    山田ひろみ, 清水惠子, 浅利優, 広瀬保江, 松田都久美, 大村友博, 間瀬田千香暁, 松原和夫, 塩野寛, 坂上和弘
    日本法医学雑誌, Apr. 2009, Japanese

  • 4‐フェニル酪酸構造類似体の合成と解析(ケミカルシャペロン活性と神経細胞死保護効果について)
    三森盛亮, 飯田博一, 清水麻希, 金子雅幸, 田窪裕介, 池永枝里花, 大村友博, 大熊康修, 浜名洋
    日本薬学会年会要旨集, Mar. 2009, Japanese

  • 4‐フェニル酪酸構造類似体の合成とそのケミカルシャペロン活性の解析
    三森盛亮, 飯田博一, 清水麻希, 金子雅幸, 田窪裕介, 池永枝里花, 大村友博, 大熊康修, 浜名洋
    メディシナルケミストリーシンポジウム講演要旨集, Nov. 2008, Japanese

  • The brain distribution of a ubiquitin ligase HRD1 in mice
    Okuma, Y, Omura, T, Kaneko, M, Nomura, Y
    Neuroscience 2008, Nov. 2008, English, International conference
    Oral presentation

  • Suppression of HRD1-mediated protein degradation causes amyloid precursor protein and beta-amyloid generation with endoplasmic reticulum stress and apoptosis
    Kaneko, M, Koike, H, Omura, T, Okuma, Y, Nomura, Y
    Neuroscience 2008, Nov. 2008, English, International conference
    Oral presentation

  • 4‐フェニル酪酸構造類似体の合成とそのケミカルシャペロン活性の解析
    三森盛亮, 飯田博一, 五十嵐麻美子, 浜名洋, 金子雅幸, 坪山沙有里, 齋藤弓子, 大村友博, 大熊康修, 松本澄
    日本薬学会年会要旨集, Mar. 2008, Japanese

  • ユビキチンリガーゼHRD1のマウス脳内局在
    大村友博, 金子雅幸, 田部井直樹, 大熊康修, 野村靖幸
    日本薬学会年会要旨集, Mar. 2008, Japanese

  • 小胞体関連分解ERADに関与するSEL1の脳内発現
    金子雅幸, 井上慎也, 大村友博, 大熊康修, 野村靖幸
    日本薬学会年会要旨集, Mar. 2008, Japanese

  • ユビキチンリガーゼHRD1の発現抑制はAPPの蓄積と小胞体ストレスによるアポトーシスを誘導する
    金子雅幸, 小池洋, 大村友博, 大熊康修, 野村靖幸
    第81回日本薬理学会年会, Mar. 2008, Japanese, Domestic conference
    Nominated symposium

  • ユビキチンリガーゼHRD1の膜貫通領域およびproline‐rich領域の機能解析
    小野口雅之, 大村友博, 金子雅幸, 野村靖幸, 大熊康修
    日本薬理学会関東部会プログラム・要旨集, 2008, Japanese

  • 小胞体のユビキチンリガーゼHRD1の減少はAPPの蓄積とA β産生増加を引き起こす
    金子雅幸, 小池洋, 大村友博, 大熊康修, 野村靖幸
    生化学, 2008, Japanese

  • 小胞体関連分解ユビキチンリガーゼによる神経変性疾患防御機構
    金子雅幸, 大村友博, 大熊康修, 野村靖幸
    日本薬学会年会要旨集, Mar. 2007, Japanese, Domestic conference
    Nominated symposium

  • ERAD関連分子HRD1によるPael‐Rの分解機構の解析
    大村友博, 金子雅幸, 大熊康修, 野村靖幸
    日本薬理学雑誌, Jan. 2007, Japanese

  • 小胞体ストレスおよびPael‐Rの凝集に対する4‐フェニル酪酸の効果
    金子雅幸, 窪田杏子, 新沼芳文, 大熊康修, 大村友博, 野村靖幸
    日本薬理学雑誌, Aug. 2006, Japanese

  • 小胞体の変性蛋白質分解関連分子HRD1によるAPPの分解とAβの産生抑制
    小池洋, 金子雅幸, 大村友博, 野村靖幸
    日本薬理学雑誌, Jan. 2005, Japanese

  • Degradation of Pael-R by human HRD1 involved in ER-associated Degradation (ERAD)
    Kaneko M, Omura T, Nomura Y
    Neuroscience 2004, Oct. 2004, English, International conference
    Oral presentation

  • ERAD(小胞体関連分解)関連蛋白質の機能解析と小胞体ストレスによる誘導機構
    金子雅幸, 新沼芳文, 石黒正太郎, 上杉麻依, 大村友博, 野村靖幸
    生体膜と薬物の相互作用シンポジウム講演要旨集, Nov. 2002, Japanese

■ Research Themes
  • ユビキチンリガーゼ活性を制御するmiRNAのパーキンソン病治療に対する有用性検証
    大村 友博
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2020 - 31 Mar. 2023
    パーキンソン病（PD）治療ではレボドパによる対症療法が主であり、新たな作用機序に基づく治療薬が期待されている。申請者はこれまでPDと小胞体ストレス関連ユビキチンリガーゼHRD1、安定化分子SEL1Lとの関連性について研究を行ってきたが、近年microRNA（miRNA）がこれら分子の発現を制御する可能性が示唆されている。 申請者は、PDモデル細胞を用いてHRD1/SEL1Lを制御するmiRNAを探索したところ、SEL1Lの発現を制御するmiRNAとしてmiR-101を見出した。今回、miR-101によるPDモデルへの影響について検討した。また、HRD1を制御するmiRNA候補についても合わせて検討した。 まず、miR-101を遺伝子導入すると、PDモデルで誘導されるSEL1Lの蛋白質発現量上昇が有意に抑制されただけでなく、HRD1の蛋白質発現量も抑制されることが明らかとなり、PDモデルで認められる細胞死が増強することが判明した。一方、miR-101 inhibitorを遺伝子導入すると、PDモデルで誘導されるSEL1Lの蛋白質発現量上昇が更に増加し、HRD1の蛋白質発現量もさらに増加することが判明し、PDモデルによる細胞死を抑制することが判明した。以上より、miR-101はSEL1Lの発現制御を介してPDモデルによける細胞死を制御することが明らかとなった。 次に、HRD1を制御するmiRNAを既報とin silicoスクリーニングで探索したところ、候補として5つのmiRNAが抽出された。そして、PDモデルを用いてmiRNAの発現量変化について検討したところ、一つのmiRNA（miR-Yとする）がHRD1を制御するmiRNA候補として見出した。今後詳細に解析する予定である。

  • Effect of renal dysfunction on the pharmacokinetics and pharmacodynamics of fluorouracil and its derivatives
    Matsubara Kazuo
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kyoto University, 01 Apr. 2017 - 31 Mar. 2020
    This study aimed to assess the changes in pharmacokinetics and pharmacodynamics of fluorouracil and its derivatives. We developed an analytical method to quantify the concentrations of fluorouracil and its metabolites in plasma and urine. Then, we examined the effect of renal dysfunction on the fluorouracil using rat models of renal disease. The result showed that the clearance of fluorouracil and its derivatives significantly decreased in rats of chronic kidney disease.

  • Functional analysis of microRNA regulating ubiquitin ligase and its component, and the application of microRNA to the treatment of brain dysfunction
    OMURA TOMOHIRO
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), 01 Apr. 2017 - 31 Mar. 2020
    In neurological diseases such as Parkinson’s disease (PD), it is difficult to assess motor function objectively, and symptomatic therapy is the only treatment at present. I have been investigating HRD1/SEL1L complex as key molecules involved in PD, and microRNAs have recently been suggested to regulate the expression of various target mRNAs and involve the onset of diverse diseases. Therefore, using PD model cells, we searched for microRNAs that regulate the expression of HRD1/SEL1L using microRNA databases. We extracted microRNA that regulates SEL1L and this microRNA also affects cell death in PD models. Taken together, these results suggest that this microRNA may be a novel pharmacotherapeutic target for PD via regulation of SEL1L expression.

  • Different etiologic mechanisms underlying HFS depending on the classes of anti-cancer agents
    Matsubara Kazuo
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Exploratory Research, Kyoto University, 01 Apr. 2015 - 31 Mar. 2017
    The present study is designed to investigate mechanisms underlying epidermal growth factor receptor inhibitors (EGFRIs)- or multikinase inhibitors (MKIs)-induced Hand-Foot Syndrome (HFS) using a human keratinocyte cell line, HaCaT cell. We evaluated the effects of EGFRIs (gefitinib and erlotinib) or MKIs (sunitinib and sorafenib) on the viability of HaCaT cells using MTT assay. Each of the anti-cancer agents reduced the viability of Schwann cells in a concentration-dependent manner after either 24 or 48 h of treatment. The treatment with gefitinib and erlotinib significantly increased the expression of apoptosis marker caspase3, and reduced phospholylated Akt (p-Akt) levels, which involves in cell survival, suggesting that EGFRIs might induce HFS via cell apoptosis mechanisms. In contrary, sunitinib and sorafenib failed to affect caspase3 and p-Akt levels. These findings clearly suggest the different etiologic mechanisms underlying HFS depending on the classes of anti-cancer agents.

  • Establishment of a method for the assessment of brain function measuring the expression level of ubiquitin ligase and its application for pharmacotherapeutics
    Omura Tomohiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kyoto University, 01 Apr. 2013 - 31 Mar. 2016
    It is very useful if we can objectively assess brain function through the measurement of marker proteins. I therefore analyze the function of ubiquitin ligase HRD1 and SEL1L, a HRD1 stabilizer, related to neurodegenerative diseases using Parkinson’s disease (PD) model cells. We confirmed that the mRNA and protein levels of HRD1 or SEL1L are upregulated in the PD model, indicating that it is possible that these molecules might be disease markers in PD. Moreover, HRD1 and SEL1L coordinated to suppress neuronal cell death in PD model, suggesting that the HRD1-SEL1L complex may potentially be one of the novel therapeutic targets in PD.

  • Genotyping of insertion/deletion polymorphisms using locked nucleic acids for human identification
    ASARI Masaru, OMURA Tomohiro, OKA Kumiko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Asahikawa Medical College, 01 Apr. 2012 - 31 Mar. 2015
    We analyzed the effects of locked nucleic acids (LNAs) for the efficiency of fluorescent labeling of PCR products. When the 24-base universal sequence with a higher Tm value was used, the introduction of a few LNAs significantly improved the efficiency, compared to the results from the 18-base universal sequence. We also selected 37 autosomal insertion/deletion (Indel) polymorphisms, and calculated the frequencies of alleles from 100 Japanese individuals. The matching probability was 2×10(-15), and the combination of selected Indels would be useful for individual discrimination. In multiplex Indel genotyping, fluorescent universal primers with LNAs produced higher signals than non-LNA fluorescent universal primers, and the increasing effects were identified especially in the low concentration (0.1 μM) of these primers.

  • Individualized L-dopa therapy in patients with Parkinson's disease
    MATSUBARA Kazuo, YONEZAWA Atsushi, FUKUDO Masahide, OMURA Tomohiro, NAKAGAWA Shunsaku
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kyoto University, 01 Apr. 2012 - 31 Mar. 2015
    L-dopa remains the gold standard for treating Parkinson's disease (PD); however, long-term L-dopa treatment is associated with motor adverse effects, particularly wearing-off. Entacapone prevents catechol-O-methyltransferase (COMT) from metabolizing L-dopa into 3-methoxy-4-hydroxy-L-phenylalanine in the periphery and ameliorates wearing-off in patients with PD treated with L-dopa for a prolonged period. In the present study, we examined whether the blood concentration of L-dopa was affected by COMT gene polymorphisms in patients taking L-dopa concomitantly with entacapone. We demonstrated that entacapone did not change the area under the blood concentration-time curve of L-dopa in PD patient who had a low-activity COMT gene. This result suggests that the blood concentration of L-dopa taken concomitantly with entacapone is affected by the COMT gene polymorphism.

  • Pathological study on cold-induced stress
    SHIMIZU KEIKO, MATSUBARA Kazuo, MASEDA Chikatoshi, ASARI Masaru, OMURA Tomohiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Asahikawa Medical College, 2011 - 2013
    No specific findings of death induced by hypothermia have been reported, although autopsies have accordingly been performed. Practically, a diagnosis of fatal hypothermia cases is established by exclusion of other known causes of death (e.g. injury, poisoning and disorder) and by relatively characteristic findings (e.g. difference in color between right and left heart blood samples, first degree frostbite, Wischnewski's spots in gastroduodenal submucous, and paradoxical undressing). It is important for finding diagnostic markers to identify the pathophysiological and molecular processes of hypothermia-induced deaths. CIRP (cold-inducible RNA-binding protein)and RBM3(RNA binding motif protein 3)are two major cold-inducible RNA-binding proteins, which are rapidly induced in human cells on exposure to moderate cold-shock. Our results suggest that immunohistochemical examinations of CIRP and RBM3 may be useful for the diagnosis of various unusual deaths in hypothermal environments.

  • Expression analysis of ubiquitin ligase HRD1 in neurodegenerative disorders and application to forensic neuropathology
    OMURA Tomohiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), 2011 - 2012
    HRD1 is reported to be involved in the pathogenesis of neurodegenerative disorders by its ubiquitin ligase activity. In the present study, we examine whether it is possible for HRD1 to be the marker of brain dysfunction. We found that HRD1 and related molecules are induced in the in vitromodels of neurodegenerative disorders. Furthermore, we demonstrated that zonisamide, an antiepileptic agent, up-regulates HRD1 and suppresses neuronal cell death.

TOP